0001564590-21-009466 | 10-K | XBRL Viewer | Acadia Healthcare Company INC

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
Document and Entity Information - USD ($) $ in Billions	Dec. 31, 2020	Feb. 26, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Trading Symbol	ACHC
Entity Registrant Name	ACADIA HEALTHCARE COMPANY, INC.
Entity Central Index Key	0001520697
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $.01 par value
Security Exchange Name	NASDAQ
Entity File Number	001-35331
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2492228
Entity Address, Address Line One	6100 Tower Circle
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	861-6000
Document Annual Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		89,039,946
Entity Public Float			$ 2.2
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement for its 2021 annual meeting of stockholders to be held on May 6, 2021 are incorporated by reference into Part III of this Form 10-K.

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 378,697	$ 99,535
Accounts receivable, net	273,551	288,863
Other current assets	61,332	64,967
Current assets held for sale	1,809,815	88,846
Total current assets	2,523,395	542,211
Property and equipment, net	1,622,896	1,499,587
Goodwill	2,105,264	2,085,104
Intangible assets, net	68,535	68,826
Deferred tax assets	3,209	3,339
Operating lease right-of-use assets	96,937	97,795
Other assets	79,126	55,106
Noncurrent assets held for sale		2,527,174
Total assets	6,499,362	6,879,142
Current liabilities:
Current portion of long-term debt	153,478	43,679
Accounts payable	87,815	90,257
Accrued salaries and benefits	124,912	93,595
Current portion of operating lease liabilities	18,916	18,119
Other accrued liabilities	178,453	69,234
Derivative instrument liabilities	84,584
Current liabilities held for sale	660,027	148,692
Total current liabilities	1,308,185	463,576
Long-term debt	2,968,948	3,105,420
Deferred tax liabilities	50,017	22,820
Operating lease liabilities	84,029	85,643
Noncurrent derivative instrument liabilities		68,915
Other liabilities	133,412	107,152
Noncurrent liabilities held for sale		487,084
Total liabilities	4,544,591	4,340,610
Redeemable noncontrolling interests	55,315	33,151
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 shares authorized; 88,024,395 and 87,715,591 issued and outstanding as of December 31, 2020 and 2019, respectively	880	877
Additional paid-in capital	2,580,327	2,557,642
Accumulated other comprehensive loss	(371,365)	(414,884)
(Accumulated deficit) retained earnings	(310,386)	361,746
Total equity	1,899,456	2,505,381
Total liabilities and equity	$ 6,499,362	$ 6,879,142

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	88,024,395	87,715,591
Common stock, shares outstanding	88,024,395	87,715,591

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenue	$ 2,089,929	$ 2,008,381	$ 1,904,695
Salaries, wages and benefits (including equity-based compensation expense of $22,504, $17,307 and $22,001, respectively)	1,154,522	1,107,357	1,049,317
Professional fees	120,489	118,451	110,049
Supplies	87,241	85,534	81,462
Rents and leases	37,362	35,486	34,315
Other operating expenses	262,272	259,536	243,671
Other income	(32,819)
Depreciation and amortization	95,256	87,923	80,342
Interest expense, net	158,105	187,325	184,534
Debt extinguishment costs	7,233		1,815
Legal settlements expense			22,076
Loss on impairment	4,751	27,217
Transaction-related expenses	11,720	21,157	29,719
Total expenses	1,906,132	1,929,986	1,837,300
Income from continuing operations before income taxes	183,797	78,395	67,395
Provision for income taxes	40,606	25,085	9,907
Income from continuing operations	143,191	53,310	57,488
(Loss) income from discontinued operations, net of taxes	(812,390)	56,812	(232,974)
Net (loss) income	(669,199)	110,122	(175,486)
Net income attributable to noncontrolling interests	(2,933)	(1,199)	(264)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$ (672,132)	$ 108,923	$ (175,750)
Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$ 1.60	$ 0.59	$ 0.66
(Loss) income from discontinued operations	(9.25)	0.65	(2.67)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	(7.65)	1.24	(2.01)
Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	1.58	0.59	0.65
(Loss) income from discontinued operations	(9.17)	0.65	(2.66)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$ (7.59)	$ 1.24	$ (2.01)
Weighted-average shares outstanding:
Basic	87,875	87,612	87,288
Diluted	88,595	87,816	87,415

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Equity-based compensation expense	$ 22,504	$ 17,307	$ 22,001

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (669,199)	$ 110,122	$ (175,486)
Other comprehensive income (loss):
Foreign currency translation gain (loss)	61,247	69,811	(127,521)
(Loss) gain on derivative instruments, net of tax of $(3.9) million, $(3.6) million and $12.7 million, respectively	(11,272)	(19,008)	36,799
Pension liability adjustment, net of tax of $(0.8) million, $(0.6) million and $0.3 million, respectively	(6,456)	(3,310)	2,463
Other comprehensive income (loss)	43,519	47,493	(88,259)
Comprehensive (loss) income	(625,680)	157,615	(263,745)
Comprehensive (income) loss attributable to noncontrolling interests	(2,933)	(1,199)	(264)
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	$ (628,613)	$ 156,416	$ (264,009)

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]
Gain (loss) on derivative instruments, tax	$ (3.9)	$ (3.6)	$ 12.7
Pension liability adjustment, tax	$ (0.8)	$ (0.6)	$ 0.3

Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	(Accumulated Deficit) Retained Earnings [Member]
Balance at Dec. 31, 2017	$ 2,572,871	$ 871	$ 2,517,545	$ (374,118)	$ 428,573
Balance, shares at Dec. 31, 2017		87,060,000
Common stock issued under stock incentive plans	$ 374	$ 3	371
Common stock issued under stock incentive plans, shares	20,989	384,000
Common stock withheld for minimum statutory taxes	$ (3,781)		(3,781)
Equity-based compensation expense	22,001		22,001
Other comprehensive income	(88,259)			(88,259)
Other	5,851		5,851
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	(175,750)				(175,750)
Balance at Dec. 31, 2018	2,333,307	$ 874	2,541,987	(462,377)	252,823
Balance, shares at Dec. 31, 2018		87,444,000
Common stock issued under stock incentive plans	$ 569	$ 3	566
Common stock issued under stock incentive plans, shares	55,671	271,000
Common stock withheld for minimum statutory taxes	$ (2,218)		(2,218)
Equity-based compensation expense	17,307		17,307
Other comprehensive income	47,493			47,493
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	108,923				108,923
Balance at Dec. 31, 2019	$ 2,505,381	$ 877	2,557,642	(414,884)	361,746
Balance, shares at Dec. 31, 2019	87,715,591	87,715,000
Common stock issued under stock incentive plans	$ 2,027	$ 3	2,024
Common stock issued under stock incentive plans, shares	68,700	309,000
Common stock withheld for minimum statutory taxes	$ (1,843)		(1,843)
Equity-based compensation expense	22,504		22,504
Other comprehensive income	43,519			43,519
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	(672,132)				(672,132)
Balance at Dec. 31, 2020	$ 1,899,456	$ 880	$ 2,580,327	$ (371,365)	$ (310,386)
Balance, shares at Dec. 31, 2020	88,024,395	88,024,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating activities:
Net (loss) income	$ (669,199)	$ 110,122	$ (175,486)
Adjustments to reconcile net income (loss) to net cash provided by continuing operating activities:
Depreciation and amortization	95,256	87,923	80,342
Amortization of debt issuance costs	12,636	11,987	10,456
Equity-based compensation expense	22,504	17,307	22,001
Deferred income taxes	53,108	1,089	(6,737)
Loss (income) from discontinued operations, net of taxes	812,390	(56,812)	232,974
Debt extinguishment costs	7,233		1,815
Legal settlements expense			22,076
Loss on impairment	4,751	27,217
Other	1,041	3,916	12,505
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	15,340	(18,714)	(19,702)
Other current assets	9,675	(501)	14,447
Other assets	1,519	(2,372)	2,725
Accounts payable and other accrued liabilities	77,993	(20,135)	7,701
Accrued salaries and benefits	9,632	5,540	15,883
Other liabilities	48,965	16,862	4,941
Net cash provided by continuing operating activities	502,844	183,429	225,941
Net cash provided by discontinued operating activities	155,963	149,475	188,139
Net cash provided by operating activities	658,807	332,904	414,080
Investing activities:
Cash paid for acquisitions, net of cash acquired		(44,900)
Cash paid for capital expenditures	(216,615)	(225,061)	(253,187)
Cash paid for real estate acquisitions	(8,349)	(7,618)	(18,383)
Proceeds from sale of property and equipment	92	11,765
Settlement of foreign currency derivatives		105,008
Other	(13,365)	12,975	(4,198)
Net cash used in continuing investing activities	(238,237)	(147,831)	(275,768)
Net cash used in discontinued investing activities	(43,602)	(53,310)	(85,196)
Net cash used in investing activities	(281,839)	(201,141)	(360,964)
Financing activities:
Borrowings on long-term debt	925,000
Borrowings on revolving credit facility	100,000	76,573
Principal payments on revolving credit facility	(100,000)	(76,573)
Principal payments on long-term debt	(41,291)	(52,984)	(39,738)
Repayment of long-term debt	(909,785)		(21,920)
Payment of debt issuance costs	(18,295)
Common stock withheld for minimum statutory taxes, net	184	(1,648)	(3,407)
Distributions to noncontrolling interests	(916)	(154)
Other	(3,146)	(4,369)	828
Net cash used in continuing financing activities	(48,249)	(59,155)	(64,237)
Net cash used in discontinued financing activities	(3,250)	(2,472)	(3,093)
Net cash used in financing activities	(51,499)	(61,627)	(67,330)
Effect of exchange rate changes on cash	4,087	3,546	(2,566)
Net increase (decrease) in cash and cash equivalents, including cash classified within current assets held for sale	329,556	73,682	(16,780)
Less: cash classified within current assets held for sale	(75,051)	(24,657)	(20,318)
Net increase in cash and cash equivalents	254,505	49,025	(37,098)
Cash and cash equivalents at beginning of the period	124,192	50,510	67,290
Cash and cash equivalents at end of the period	378,697	99,535	30,192
Supplemental Cash Flow Information:
Cash paid for interest	137,578	173,239	175,204
Cash (received) paid for income taxes	(16,486)	31,915	$ 6,136
Effect of acquisitions:
Assets acquired, excluding cash	20,200	48,594
Liabilities assumed	(53)	(3,694)
Redeemable noncontrolling interest resulting from an acquisition	$ (20,147)
Cash paid for acquisitions, net of cash acquired		$ 44,900

Description of Business and Basis of Presentation

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

1. Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities in which the Company operates. At December 31, 2020, the Company operated 572 behavioral healthcare facilities with approximately 18,100 beds in 40 states, the United Kingdom (“U.K.”) and Puerto Rico.

On January 19, 2021, the Company completed the sale of its U.K. operations to RemedcoUK Limited, a company organized under the laws of England and Wales and owned by funds managed or advised by Waterland Private Equity Fund VII (the “U.K. Sale”). The U.K. Sale allows us to reduce our indebtedness and focus on our United States (“U.S.”) operations. As a result of the U.K. Sale, the Company reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements. See Note 3 – U.K. Sale.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its’ direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The majority of the Company’s expenses are “cost of revenue” items. Costs that could be classified as general and administrative expenses include the Company’s corporate office costs, which were $97.8 million, $90.4 million and $86.6 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Certain reclassifications have been made to prior years to conform to the current year presentation.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, cash and cash equivalent balances may exceed federally insured limits. Management believes that the Company mitigates any risks by depositing cash and investing in cash equivalents with major financial institutions.

Insurance

The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides. A portion of the Company’s professional liability risks are insured through a wholly-owned insurance subsidiary. The Company is self-insured for professional liability claims up to $3.0 million per claim and has obtained reinsurance coverage from a third party to cover claims in excess of the retention limit. The reinsurance policy has a coverage limit of $75.0 million in the aggregate. The Company’s reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place. The reserve for professional and general liability risks was estimated based on historical claims, demographic factors, industry trends, severity factors, and other actuarial assumptions. The estimated accrual for professional and general liabilities could be significantly affected should current and future occurrences differ from historical claim trends and expectations. While claims are monitored closely when estimating professional and general liability accruals, the complexity of the claims and wide range of potential outcomes often hampers timely adjustments to the assumptions used in these estimates. The professional and general liability reserve was $77.5 million at December 31, 2020, of which $9.7 million was included in other accrued liabilities and $67.8 million was included in other long-term liabilities. The professional and general liability reserve was $52.6 million at December 31, 2019, of which $4.7 million was included in other accrued liabilities and $47.9 million was included in other long-term liabilities. The Company estimates receivables for the portion of professional and general liability reserves that are recoverable under the Company’s insurance policies. Such receivable was

$27.2 million at December 31, 2020, of which $6.8 million was included in other current assets and $20.4 million was included in other assets, and such receivable was $8.5 million at December 31, 2019, of which $3.0 million was included in other current assets and $5.5 million was included in other assets.

The Company’s statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. The workers’ compensation liability was $23.0 million at December 31, 2020, of which $12.0 million was included in accrued salaries and benefits and $11.0 million was included in other long-term liabilities, and such liability was $20.8 million at December 31, 2019, of which $10.0 million was included in accrued salaries and benefits and $10.8 million was included in other long-term liabilities. The reserve for workers compensation claims was based upon independent actuarial estimates of future amounts that will be paid to claimants. Management believes that adequate provisions have been made for workers’ compensation and professional and general liability risk exposures.

Property and Equipment and Other Long-Lived Assets

Property and equipment are recorded at cost. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets, which typically range from 10 to 50 years for buildings and improvements, three to seven years for equipment and the shorter of the lease term or estimated useful lives for leasehold improvements. When assets are sold or retired, the corresponding cost and accumulated depreciation are removed from the related accounts and any gain or loss is recorded in the period of sale or retirement. Repair and maintenance costs are expensed as incurred. Depreciation expense was $95.3 million, $87.9 million and $80.3 million for the years ended years ended December 31, 2020, 2019 and 2018, respectively.

The carrying values of long-lived assets are reviewed for possible impairment whenever events, circumstances or operating results indicate that the carrying amount of an asset may not be recoverable. If this review indicates that the asset will not be recoverable, as determined based upon the undiscounted cash flows of the operating asset over the remaining useful lives, the carrying value of the asset will be reduced to its estimated fair value. Fair value estimates are based on independent appraisals, market values of comparable assets or internal evaluations of future net cash flows.

The Company performed an impairment review of long-lived assets in the fourth quarters of 2020 and 2019, which indicated the carrying amounts of certain of the Company’s long-lived assets in facilities in the U.S. (the “U.S. Facilities”) may not be recoverable. This created a non-cash impairment of $4.2 million and $27.2 million for the years ended December 31, 2020 and 2019, respectively. These items were recorded in loss on impairment on our consolidated statements of operations. No impairment was recorded for the year ended December 31, 2018.

Goodwill and Indefinite-Lived Intangible Assets

The Company’s goodwill and other indefinite-lived intangible assets, which consist of licenses and accreditations, trade names and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate the carrying value of a reporting unit may not be recoverable. As of the Company’s annual impairment test on October 1, 2020, we had two operating segments for segment reporting purposes, U.S. Facilities and facilities in the U.K. (the “U.K. Facilities”), each of which represents a reporting unit for purposes of the Company’s goodwill impairment test.

The Company’s annual goodwill impairment and other indefinite-lived intangible assets test performed as of October 1, 2020 considered recent financial performance, including the impacts of COVID-19 on certain portions of the U.K. business. The 2020 impairment test of the U.K. Facilities indicated carrying value of the reporting unit exceeded the estimated fair value and resulted in a non-cash loss on impairment of the remaining goodwill of the U.K. Facilities of $356.2 million. The non-cash loss impairment is included in loss on sale within discontinued operations in the consolidated statements of operations. As of the Company’s impairment test on October 1, 2020, the fair value of our U.S Facilities reporting unit substantially exceeded its carrying value, and therefore no impairment was recorded. Additionally, for the year ended December 31, 2020, the Company recorded a non-cash impairment charge of $0.6 million related to indefinite-lived assets related to closed facilities in the U.S., which is included in loss on impairment in the consolidated statements of operations.

Due to the classification of the U.K. Facilities in discontinued operations at December 31, 2020, the Company now has one operating segment, behavioral health services, for segment reporting purposes. The behavioral healthcare services operating segment represents one reporting unit for future goodwill impairment tests.

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2020		2019
Prepaid expenses	$	19,480	$	17,343
Workers’ compensation deposits – current portion		12,000		10,000
Other receivables		10,025		10,661
Insurance receivable – current portion		6,792		3,030
Cost report receivable		5,818		13,723
Inventory		4,851		4,075
Income taxes receivable		897		4,786
Other		1,469		1,349
Other current assets	$	61,332	$	64,967

Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2020		2019
Accrued interest	$	40,479	$	33,323
Unearned income		35,946		1,895
Finance lease liabilities		32,188		3,765
Accrued expenses		28,452		18,595
Income taxes payable		16,345		—
Insurance liability – current portion		9,700		4,731
Accrued property taxes		6,763		4,755
Government relief funds		5,495		—
Other		3,085		2,170
Other accrued liabilities	$	178,453	$	69,234

Stock Compensation

The Company measures and recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, “ Compensation—Stock Compensation .” The Company uses the Black-Scholes valuation model to determine grant-date fair value for stock options and recognizes straight-line amortization of share-based compensation expense over the requisite service period of the respective awards. The fair values of restricted stock units are determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at their Monte-Carlo simulation value for units subject to market conditions.

Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with FASB ASC 260, “Earnings Per Share,” based on the weighted-average number of shares outstanding in each period and dilutive stock options and non-vested shares, to the extent such securities have a dilutive effect on earnings per share.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date.

The Company reviews its deferred tax assets for recoverability and establishes a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in income tax expense.

The Company has accruals for taxes and associated interest that may become payable in future years as a result of audits by tax authorities. The Company accrues for tax contingencies when it is more likely than not that a liability to a taxing authority has been incurred and the amount of the contingency can be reasonably estimated. Although Management believes that the positions taken on previously filed tax returns are reasonable, we nevertheless have established tax and interest reserves in recognition that various taxing authorities may challenge the positions taken by us resulting in additional liabilities for taxes and interest. These amounts are reviewed as circumstances warrant and adjusted as events occur that affect our potential liability for additional taxes, such as lapsing of applicable statutes of limitations, conclusion of tax audits, additional exposure based on current calculations, identification of new issues, release of administrative guidance, or rendering of a court decision affecting a particular tax issue.

Recent Accounting Pronouncements

In March 2020, the SEC adopted final rules that amend Rule 3-10 and Rule 3-16 of Regulation S-X to reduce and simplify the financial disclosure requirements applicable to guarantors and issuers of guaranteed securities, as well as for affiliates whose securities collateralize a registrant’s securities. The new rules are effective January 4, 2021. Early adoption is permitted. The Company early adopted the new rules during the second quarter of 2020.

In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting and applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 is effective as of March 12, 2020 through December 31, 2022. Entities may adopt ASU 2020-04 as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020 or prospectively from a date within an interim period that includes or is subsequent to March 12, 2020, up to the date that the financial statements are available to be issued. Management is evaluating the impact of ASU 2020-04 on the Company’s consolidated financial statements.

In August 2018, the FASB issued Accounting Standards Update (“ASU”) 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU 2018-15”). ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-402 to determine which implementation costs to capitalize as assets. ASU 2018-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted ASU 2018-15 on January 1, 2020. There is no significant impact on the Company’s consolidated financial statements.

In August 2017, FASB issued ASU 2017-12, “Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities” (“ASU 2017-12”). ASU 2017-12 amends the hedge accounting model to enable entities to better portray the economics of their risk management activities in the financial statements and simplifies the application of hedge accounting in certain situations. ASU 2017-12 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. The Company adopted ASU 2017-12 on January 1, 2019. There is no significant impact on the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). ASU 2016-13 replaces the current incurred loss impairment methodology with a new methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted ASU 2016-13 on January 1, 2020. There is no significant impact on the Company’s consolidated financial statements.

U.K. Sale

12 Months Ended

Dec. 31, 2020

Discontinued Operations And Disposal Groups [Abstract]

U.K. Sale

3. U.K. Sale

On January 19, 2021, the Company completed the U.K. Sale pursuant to a Share Purchase Agreement in which it sold all of the securities of AHC-WW Jersey Limited, a private limited liability company incorporated in Jersey and a subsidiary of the Company, which constitutes the entirety of our U.K. business operations. The U.K. Sale resulted in approximately $1,525 million of gross proceeds before deducting the settlement of existing foreign currency hedging liabilities of $85 million based on the current British Pounds (“GBP”) to US Dollars (“USD”) exchange rate, cash retained by the buyer of approximately $75 million and transaction costs of $16 million. The Company used the net proceeds of approximately $1,425 million (or $1,350 million, net of cash retained by the buyer) to repay in full the outstanding balances of its Term Loan A Facility (the “TLA Facility”) of $312 million and its Term Loan B facility Tranche B-4 (the “Tranche B-4 Facility”) of $768 million of the Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) and added $345 million of cash to the Company’s balance sheet. In addition to reducing its indebtedness, the U.K. Sale allows the Company to focus on U.S. operations.

As a result of the U.K. Sale, the Company reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements. In December 2020, the Company’s U.K. operations met the criteria to be classified as assets held for sale. The carrying value of the U.K. operations was written down to fair value less costs to sell in the consolidated balance sheets at December 31, 2020. This resulted in a loss on sale of $867.3 million, which includes approximately $356.2 million of non-cash goodwill impairment, within discontinued operations in the consolidated statements of operations.

For the years ended December 31, 2020, 2019 and 2018, results of operations of the U.K. operations were as follows (in thousands):

	Year Ended December 31,
	2020			2019			2018
Revenue	$	1,119,768		$	1,099,081		$	1,107,747
Salaries, wages and benefits		632,134			609,823			610,031
Professional fees		127,291			122,532			117,376
Supplies		38,285			37,527			37,852
Rents and leases		47,748			46,743			45,967
Other operating expenses		113,534			115,897			110,827
Depreciation and amortization		74,935			76,121			78,490
Interest expense, net		(417	)		(231	)		876
Loss on sale		867,324			—			—
Loss on impairment		20,239			27,169			337,889
Transaction-related expenses		8,719			5,907			4,788
Total expenses		1,929,792			1,041,488			1,344,096
(Loss) income from discontinued operations before income taxes		(810,024	)		57,593			(236,349	)
Provision for (benefit from) income taxes		2,366			781			(3,375	)
(Loss) income from discontinued operations	$	(812,390	)	$	56,812		$	(232,974	)

The major classes of assets and liabilities for the U.K. operations are shown below (in thousands):

	December 31,
	2020		2019

Cash and cash equivalents	$	75,051	$	24,657
Accounts receivable, net		52,196		50,912
Other current assets		13,361		13,277
Current assets of discontinued operations		140,608		88,846
Property and equipment, net		1,297,923		1,724,447
Goodwill		—		364,027
Intangible assets, net		22,289		21,531
Operating lease right-of-use assets		341,289		404,042
Other assets		7,706		13,127
Total assets of discontinued operations		1,809,815		2,616,020

Current liabilities:
Accounts payable	$	44,929	$	36,788
Current portion of operating lease liabilities		11,141		11,021
Other current liabilities		136,895		100,883
Current liabilities of discontinued operations		192,965		148,692
Operating lease liabilities		387,607		416,609
Deferred tax liabilities		57,230		49,040
Other liabilities		22,225		21,435
Total liabilities of discontinued operations	$	660,027	$	635,776

As part of the acquisition of Partnerships in Care on July 1, 2014, the Company assumed a frozen contributory defined benefit retirement plan (“Partnerships in Care Pension Plan”) covering substantially all of the employees of Partnerships in Care and its subsidiaries prior to May 1, 2005 at which time, the Partnerships in Care Plan was frozen to new participants. Effective May 2015, the active participants no longer accrue benefits. The Company recognizes the unfunded liability of the Partnerships in Care Pension Plan on the Company’s consolidated balance sheet and unrecognized gains (losses) and prior service credits (costs) as changes in other comprehensive income (loss). The measurement date of the Partnerships in Care Pension Plan’s assets and liabilities coincides with the Company’s year-end. The Company’s pension benefit obligation is measured using actuarial calculations that incorporate discount rates, rate of compensation increases, when applicable, expected long-term returns on plan assets and consider expected age of retirement and mortality. Expected return on plan assets is determined by using the specific asset distribution at the measurement date.

The following table summarizes the funded status (unfunded liability) of the Partnerships in Care Pension Plan based upon actuarial valuations prepared at December 31, 2020 and 2019 (in thousands). The unfunded liability for the Partnership in Care Pension Plan is included in current liabilities held for sale and noncurrent liabilities held for sale, respectively, on the consolidated balance sheets at December 31, 2020 and 2019. The Company’s obligation to maintain the Partnership in Care Pension Plan terminated effective January 19, 2021 in connection with the U.K. Sale.

	2020		2019
Projected benefit obligation	$	80,158	$	66,468
Fair value of plan assets		71,979		62,207
Unfunded liability	$	8,179	$	4,261

The consolidated cash flows for the years ended December 31, 2020 and 2019 related to the discontinued U.K. operations includes cash paid for capital expenditures of $48.4 million and $59.6 million, respectively.

The CARES Act

12 Months Ended

Dec. 31, 2020

Extraordinary And Unusual Items [Abstract]

The CARES Act

4. The CARES Act

As part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), the U.S. government announced it would offer $100 billion of relief to eligible healthcare providers. On April 24, 2020, President Trump signed into law the Paycheck Protection Program and Health Care Enhancement Act (the “New PPP Act”). Among other things, the New PPP Act allocates $75 billion to eligible healthcare providers to help offset COVID-19 related losses and expenses. The $75 billion allocated under the New PPP Act is in addition to the $100 billion allocated to healthcare providers for the same purposes in the CARES Act and has been disbursed to providers under terms and conditions similar to the CARES Act funds. During the three months ended June 30, 2020, the Company participated in certain relief programs offered through the CARES Act, including receipt of approximately $19.7 million relating to the initial portions of the Public Health and Social Services Emergency Fund (“PHSSE Fund”), also known as the Provider Relief Fund, and approximately $45 million of payments from the Centers for Medicare and Medicaid Services’ (“CMS”) Accelerated and Advance Payment Program. The Company expects to repay these funds over a 12-month period beginning in April 2021. Once repayment begins, the amount will be recouped from the Company’s new Medicare claims. In August 2020, the Company received approximately $12.8 million of additional funds from the PHSSE Fund. In addition, the Company received a 2% increase in facilities’ Medicare reimbursement rate as a result of the temporary suspension of Medicare sequestration from May 1, 2020, to March 31, 2021.

The CARES Act also provides for certain federal income and other tax changes, including an increase in the interest expense tax deduction limitation and bonus depreciation of qualified improvement property. Furthermore, under the CARES Act, (i) for taxable years beginning before 2021, net operating loss (“NOL”) carryforwards and carrybacks may offset 100% of taxable income and (ii) NOLs arising in 2018, 2019 and 2020 taxable years may be carried back to each of the preceding five years to generate a refund. As a result, in 2019 and 2020 the Company received a benefit, in the form of refunds and lower future tax payments, of $51.6 million, consisting of $22.8 million related to interest expense, $20.5 million related to qualified improvement property legislation and an $8.3 million permanent benefit due to the loss being able to be carried back at a 35% tax rate to offset income in tax years prior to 2018 (21% for tax years after 2017). The Company also received a cash benefit of approximately $39 million for 2020 relating to the delay of payment of the employer portion of Social Security payroll taxes, as enacted by the CARES Act.

During the fourth quarter of 2020, the Company recorded $32.8 million of other income in the consolidated statement of operations related to $34.9 million of PHSSE funds received from April through December 2020. The Company’s recognition of this income was based on revised guidance in the Consolidated Appropriations Act, 2021 enacted in December 2020. The Company continues to evaluate its compliance with the terms and conditions to, and the financial impact of, funds received under the CARES Act and other government relief programs.

Revenue

12 Months Ended

Dec. 31, 2020

Revenue From Contract With Customer [Abstract]

Revenue

5. Revenue

Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract.

Services ordered by a healthcare provider in an episode of care are not separately identifiable and therefore have been combined into a single performance obligation for each contract. The Company recognizes revenue as its performance obligations are completed. The performance obligation is satisfied over time as the customer simultaneously receives and consumes the benefits of the healthcare services provided. For inpatient services, the Company recognizes revenue equally over the patient stay on a daily basis. For outpatient services, the Company recognizes revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payors are billed within several days of the service being performed or the patient being discharged, and payments are due based on contract terms.

As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.

At December 31, 2020 and 2019, estimated implicit price concessions of $62.1 million and $45.9 million, respectively, had been recorded as reductions to our accounts receivable balances to enable us to record our revenues and accounts receivable at the estimated amounts we expected to collect. The adoption of ASU 2014-09 did not have a significant impact on the Company’s consolidated statements of operations.

The Company disaggregates revenue from contracts with customers by service type and by payor.

The Company’s U.S. Facilities and services provided by the U.S. Facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; residential treatment centers; and outpatient community-based facilities.

Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists.

Specialty treatment facilities. Specialty treatment facilities include residential recovery facilities, eating disorder facilities and comprehensive treatment centers. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care.

Residential treatment centers. Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities.

Outpatient community-based facilities. Outpatient community-based programs are designed to provide therapeutic treatment to children and adolescents who have a clinically-defined emotional, psychiatric or chemical dependency disorder while enabling the youth to remain at home and within their community.

The table below presents total U.S. revenue attributed to each category (in thousands):

	Year Ended December 31,
	2020		2019		2018
Acute inpatient psychiatric facilities	$	984,609	$	912,097	$	814,124
Specialty treatment facilities		802,022		788,232		761,017
Residential treatment centers		281,158		286,959		293,053
Outpatient community-based facilities		22,140		21,093		36,501
Revenue	$	2,089,929	$	2,008,381	$	1,904,695

The Company receives payments from the following sources for services rendered in our U.S. Facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”); and (iv) individual patients and clients.

The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of our U.S. Facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the consolidated statements of operations. Bad debt expense for the years ended December 31, 2020 and 2019 was not significant.

The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be estimated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s cost report receivables were $5.8 million and $13.7 million for the years ended December 31, 2020 and 2019, respectively, and were included in other

current assets in the consolidated balance sheets. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount. The net adjustments to estimated cost report settlements resulted in a decreases to revenue of $1.3 million and $0.4 million for the years ended December 31, 2020 and 2019, respectively, and an increase to revenue of $0.5 million for the year ended December 31, 2018.

The Company provides care without charge to patients who are financially unable to pay for the healthcare services they receive based on Company policies and federal and state poverty thresholds. Such amounts determined to qualify as charity care are not reported as revenue. The cost of providing charity care services were $4.4 million, $4.3 million and $4.7 million for the years ended December 31, 2020, 2019 and 2018, respectively. The estimated cost of charity care services was determined using a ratio of cost to gross charges determined from our most recently filed Medicare cost reports and applying that ratio to the gross charges associated with providing charity care for the period.

The following table presents revenue by payor type and as a percentage of revenue in our U.S. Facilities for the years ended December 31, 2020, 2019 and 2018 (in thousands):

	Year Ended December 31,
	2020					2019					2018
	Amount		%			Amount		%			Amount		%
Commercial	$	596,698		28.5	%	$	565,350		28.2	%	$	573,089		30.1	%
Medicare		330,070		15.8	%		294,691		14.7	%		280,340		14.7	%
Medicaid		1,037,852		49.7	%		1,007,102		50.1	%		893,644		46.9	%
Self-Pay		98,302		4.7	%		118,716		5.9	%		134,054		7.1	%
Other		27,007		1.3	%		22,522		1.1	%		23,568		1.2	%
Revenue	$	2,089,929		100.0	%	$	2,008,381		100.0	%	$	1,904,695		100.0	%

Contract liabilities in the U.S. Facilities primarily consisted of unearned revenue from CMS’ Accelerated and Advance Payment Program. In April 2020, the Company received approximately $45 million from CMS’ Accelerated and Advance Payment Program for Medicare providers, which the Company expects to repay over the 12 month period beginning in April 2021. Once repayment begins, the amount will be recouped from the provider’s or supplier’s new Medicare claims. Approximately $35.9 million and $11.3 million of contract liabilities are included in other accrued liabilities and other liabilities, respectively, on the consolidated balance sheets. A summary of the activity in unearned revenue in the U.S. Facilities is as follows (in thousands):

Balance at December 31, 2019	$	1,895
Payments received		51,044
Revenue recognized		(5,743	)
Balance at December 31, 2020	$	47,196

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Earnings Per Share

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Earnings Per Share

6. Earnings Per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2020, 2019 and 2018 (in thousands, except per share amounts):

	Year Ended December 31,
	2020			2019		2018
Numerator:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	140,258		$	52,111	$	57,224
(Loss) income from discontinued operations		(812,390	)		56,812		(232,974	)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	(672,132	)	$	108,923	$	(175,750	)
Denominator:
Weighted average shares outstanding for basic earnings per share		87,875			87,612		87,288
Effects of dilutive instruments		720			204		127
Shares used in computing diluted earnings per common share		88,595			87,816		87,415

Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	1.60		$	0.59	$	0.66
(Loss) income from discontinued operations		(9.25	)		0.65		(2.67	)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	(7.65	)	$	1.24	$	(2.01	)

Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	1.58		$	0.59	$	0.65
(Loss) income from discontinued operations		(9.17	)		0.65		(2.66	)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	(7.59	)	$	1.24	$	(2.01	)

Approximately 1.9 million, 2.2 million and 1.9 million shares of common stock issuable upon exercise of outstanding stock options were excluded from the calculation of diluted earnings per share for the years ended December 31, 2020, 2019 and 2018, respectively, because their effect would have been anti-dilutive.

Acquisitions

12 Months Ended

Dec. 31, 2020

Business Combinations [Abstract]

Acquisitions

7. Acquisitions

The Company’s strategy is to acquire and develop behavioral healthcare facilities and improve operating results within its facilities and its other behavioral healthcare operations.

On April 1, 2019, the Company completed the acquisition of Bradford Recovery Center, a specialty treatment facility with 46 beds located in Millerton, Pennsylvania, for cash consideration of approximately $4.5 million.

On February 15, 2019, the Company completed the acquisition of Whittier Pavilion, an inpatient psychiatric facility with 71 beds located in Haverhill, Massachusetts, for cash consideration of approximately $17.9 million. Also on February 15, 2019, the Company completed the acquisition of Mission Treatment for cash consideration of approximately $22.5 million and a working capital settlement. Mission Treatment operates nine comprehensive treatment centers in California, Nevada, Arizona and Oklahoma.

Goodwill

The following table summarizes changes in goodwill for the years 2019 and 2020 (in thousands):

Balance at January 1, 2019	$	2,044,837
Increase from contribution of redeemable noncontrolling interests		3,300
Increase from 2019 acquisitions		36,967
Goodwill at December 31, 2019		2,085,104
Increase from contribution of redeemable noncontrolling interests		20,200
Adjustments related to 2019 acquisitions		(40	)
Goodwill at December 31, 2020	$	2,105,264

Transaction-related expenses

Transaction-related expenses represent costs primarily related to termination, restructuring, strategic review, management transition and other acquisition-related costs. Transaction-related expenses comprised the following costs for the years ended years ended December 31, 2020, 2019 and 2018 (in thousands):

	Year Ended December 31,
	2020		2019		2018
Legal, accounting and other acquisition-related costs	$	8,252	$	3,030	$	3,152
Termination, restructuring and strategic review costs		3,468		12,598		12,534
Management transition costs		—		5,529		14,033
	$	11,720	$	21,157	$	29,719

Property and Equipment

12 Months Ended

Dec. 31, 2020

Property Plant And Equipment [Abstract]

Property and Equipment

8. Property and Equipment

Property and equipment consisted of the following at December 31, 2020 and 2019 (in thousands):

	December 31,
	2020			2019
Land	$	144,221		$	138,325
Building and improvements		1,490,149			1,275,610
Equipment		220,690			199,264
Construction in progress		217,479			247,467
		2,072,539			1,860,666
Less: accumulated depreciation		(449,643	)		(361,079	)
Property and equipment, net	$	1,622,896		$	1,499,587

During the years ended December 31, 2020 and 2019, the Company recorded non-cash impairment charges of $4.2 million and $27.2 million, respectively, related to the closure of certain facilities. The Company has recorded assets held for sale within other assets on the consolidated balance sheets for closed U.S. properties actively marketed of $17.1 million and $18.9 million at December 31, 2020 and 2019, respectively.

Other Intangible Assets

12 Months Ended

Dec. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Other Intangible Assets

9. Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following at December 31, 2020 and 2019 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	December 31, 2020		December 31, 2019		December 31, 2020			December 31, 2019
Intangible assets subject to amortization:
Contract intangible assets	$	—	$	2,100	$	—		$	(2,100	)
Non-compete agreements		1,131		1,131		(1,131	)		(1,131	)
		1,131		3,231		(1,131	)		(3,231	)
Intangible assets not subject to amortization:
Licenses and accreditations		11,873		12,020		—			—
Trade names		39,526		39,735		—			—
Certificates of need		17,136		17,071		—			—
		68,535		68,826		—			—
Total	$	69,666	$	72,057	$	(1,131	)	$	(3,231	)

All the Company’s definite-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization. For the year ended December 31, 2020, the Company recorded a non-cash impairment charge of $0.6 million related to indefinite-lived assets related to closed facilities in the U.S., which is included in loss on impairment in the consolidated statements of operations.

Leases

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Leases

10. Leases

The Company’s lease portfolio primarily consists of finance and operating real estate leases integral for facility operations. The original terms of the leases typically range from five to 30 years with optional renewal periods. A minimal portion of the Company’s lease portfolio consists of non-real estate leases, including copiers and equipment, which generally have lease terms of one to three years and have insignificant lease obligations.

The Company also elected the accounting policy practical expedients by class of underlying asset in ASC 842 “Leases” to: (i) combine associated lease and non-lease components into a single lease component; and (ii) exclude recording short-term leases as right-of-use assets and liabilities on the consolidated balance sheets. Non-lease components, which are not significant overall, are combined with lease components.

Operating lease liabilities are recorded at the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for prepayments, accrued lease payments, lease incentives and initial direct costs. Certain of the Company’s leases include renewal or termination options. Calculation of operating lease right-of-use assets and liabilities include the initial lease term unless it is reasonably certain a renewal or termination option will be exercised. Variable components of lease payments fluctuating with a future index or rate, as well as those related to common area maintenance costs, are not included in determining lease payments and are expensed as incurred. Most of the Company’s leases do not contain implicit borrowing rates, and therefore, incremental borrowing rates were calculated based on information available at the later of the lease commencement date. The Company reviews service agreements for embedded leases and records right-of-use assets and liabilities as necessary.

Lease Position

The Company recorded the following at December 31, 2020 and 2019 on the consolidated balance sheet (in thousands):

Right-of-Use Assets	Balance Sheet Classification	December 31, 2020		December 31, 2019
Finance lease right-of-use assets	Property and equipment, net	$	34,621	$	35,489
Operating lease right-of-use assets	Operating lease right-of-use assets		96,937		97,795
Total		$	131,558	$	133,284

Lease Liabilities	Balance Sheet Classification	December 31, 2020		December 31, 2019
Current:
Finance lease liabilities	Other accrued liabilities	$	32,188	$	3,765
Operating lease liabilities	Current portion of operating lease liabilities		18,916		18,119
Noncurrent:
Finance lease liabilities	Other liabilities		10,744		39,719
Operating lease liabilities	Operating lease liabilities		84,029		85,643
Total		$	145,877	$	147,246

Weighted-average remaining lease terms and discount rates were as follows at December 31, 2020 and 2019:

	December 31,
	2020			2019
Weighted-average remaining lease term (in years):
Finance	6.7			6.5
Operating	8.5			8.6

Weighted-average discount rate:
Finance		5.9	%		5.3	%
Operating		6.5	%		6.5	%

Lease Costs

The Company recorded the following lease costs at December 31, 2020 and 2019 (in thousands):

	December 31,
	2020		2019
Finance lease costs:
Depreciation of leased assets		868		907
Interest of lease liabilities		3,214		3,226
Total finance lease costs	$	4,082	$	4,133

Operating lease costs		27,050		25,630
Variable lease costs		2,501		1,966
Short term lease costs		3,558		4,790
Other lease costs		4,253		3,101
Total rents and leases	$	37,362	$	35,487

Total lease costs	$	41,444	$	39,620

Other

Undiscounted cash flows for finance and operating leases recorded on the consolidated balance sheet were as follows at December 31, 2020 (in thousands):

	Finance Leases		Operating Leases
2021	$	32,909	$	25,015
2022		990		21,032
2023		990		17,336
2024		1,007		14,832
2025		1,089		12,101
Thereafter		23,999		52,866
Total minimum lease payments		60,984		143,182
Less: amount of lease payments representing interest		18,052		40,237
Present value of future minimum lease payments		42,932		102,945
Less: Current portion of lease liabilities		32,188		18,916
Noncurrent lease liabilities	$	10,744	$	84,029

Supplemental data for the years ended December 31, 2020 and 2019 were as follows (in thousands):

	December 31,
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	26,810	$	25,086
Operating cash flows for finance leases	$	3,214	$	3,226
Financing cash flows for finance leases	$	551	$	862

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	21,285	$	21,809
Finance leases	$	-	$	-

Long-Term Debt

12 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Long-Term Debt

11. Long-Term Debt

Long-term debt consisted of the following (in thousands):

	December 31,
	2020			2019
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loan	$	311,733		$	346,750
Senior Secured Term B Loans		872,870			1,338,928
Senior Secured Revolving Line of Credit		—			—
6.125% Senior Notes due 2021		—			150,000
5.125% Senior Notes due 2022		—			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			390,000
5.500% Senior Notes due 2028		450,000			—
5.000% Senior Notes due 2029		475,000			—
Other long-term debt		3,625			4,821
Less: unamortized debt issuance costs, discount and premium		(30,802	)		(31,400	)
		3,122,426			3,149,099
Less: current portion		(153,478	)		(43,679	)
Long-term debt	$	2,968,948		$	3,105,420

Amended and Restated Senior Credit Facility

The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”). The Company has amended the Amended and Restated Credit Agreement from time to time as described in the Company’s prior filings with the SEC.

On March 22, 2018, the Company entered into a Second Repricing Facilities Amendment (the “Second Repricing Facilities Amendment”) to the Amended and Restated Credit Agreement. The Second Repricing Facilities Amendment (i) replaced the Term Loan B facility Tranche B-1 (the “Tranche B-1 Facility”) and the Term Loan B facility Tranche B-2 (the “Tranche B-2 Facility”) with a new Term Loan B facility Tranche B-3 (the “Tranche B-3 Facility”) and a new Term Loan B facility Tranche B-4 (the “Tranche B-4 Facility”), respectively, and (ii) reduced the Applicable Rate from 2.75% to 2.50% in the case of Eurodollar Rate loans and reduced the Applicable Rate from 1.75% to 1.50% in the case of Base Rate Loans.

On March 29, 2018, the Company entered into a Third Repricing Facilities Amendment to the Amended and Restated Credit Agreement (the “Third Repricing Facilities Amendment”, and together with the Second Repricing Facilities Amendment, the “Repricing Facilities Amendments”). The Third Repricing Facilities Amendment replaced the existing revolving credit facility and Term Loan A facility (“TLA Facility”) with a new revolving credit facility and TLA Facility, respectively. The Company’s line of credit on its revolving credit facility remains at $500.0 million and the Third Repricing Facility Amendment reduced the size of the TLA Facility from $400.0 million to $380.0 million to reflect the then current outstanding principal. The Third Repricing Facilities Amendment reduced the Applicable Rate by 25 basis points for the revolving credit facility and the TLA Facility by amending the definition of “Applicable Rate.” In connection with the Repricing Facilities Amendments, the Company recorded a debt extinguishment charge of $0.9 million, including the discount and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of operations.

On February 6, 2019, the Company entered into the Eleventh Amendment (the “Eleventh Amendment”) to the Amended and Restated Credit Agreement. The Eleventh Amendment, among other things, amended the definition of “Consolidated EBITDA” to remove the cap on non-cash charges, losses and expenses related to the impairment of goodwill, which in turn provided increased flexibility to the Company in terms of the Company’s financial covenants.

On February 27, 2019, the Company entered into the Twelfth Amendment (the “Twelfth Amendment”) to the Amended and Restated Credit Agreement. The Twelfth Amendment, among other things, modified certain definitions, including “Consolidated EBITDA”, and increased our permitted Maximum Consolidated Leverage Ratio, thereby providing increased flexibility to the Company in terms of the Company’s financial covenants.

On April 21, 2020, the Company entered into the Thirteenth Amendment (the “Thirteenth Amendment”) to the Amended and Restated Credit Agreement. The Thirteenth Amendment amended the Consolidated Leverage Ratio in the existing covenant to increase the leverage ratio for the rest of 2020.

On November 13, 2020, the Company entered into the Fourth Repricing Facilities Amendment (the “Fourth Repricing Facilities Amendment”) to the Amended and Restated Credit Agreement. The Fourth Repricing Facilities Amendment extended the maturity date of each of the existing revolving line of credit and the existing TLA Facility from November 30, 2021 to November 30, 2022. The Fourth Repricing Facilities Amendment also (1) replaced the revolving line of credit in an aggregate committed amount of $500.0 million to an aggregate committed amount of approximately $459.0 million and (2) replaced the TLA Facility aggregate outstanding principal amount of approximately $352.4 million to an aggregate principal amount of approximately $318.9 million. The interest rate margin applicable to both facilities remains unchanged from the prior facilities, and the commitment fee applicable to the new revolving line of credit also remains unchanged from the prior revolving line of credit. In connection with the Fourth Repricing Facilities Amendment, the Company recorded a debt extinguishment charge of $1.0 million, including the write-off of discount and deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of operations.

On January 5, 2021, the Company made a voluntary payment of $105.0 million on the Tranche B-4 Facility. On January 19, 2021, the Company used a portion of the net proceeds from the U.K. Sale to repay $311.7 million of its TLA Facility and $767.9 million of its Tranche B-4 Facility of the Amended and Restated Credit Agreement.

The Company had $441.6 million of availability under the revolving line of credit and had standby letters of credit outstanding of $17.4 million related to security for the payment of claims required by its workers’ compensation insurance program at December 31, 2020. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our TLA Facility of $9.5 million

for March 31, 2021 to September 30, 2022, with the remaining principal balance of the TLA Facility due on the maturity date of November 30, 2022. The Company is required to repay the Tranche B-4 Facility in equal quarterly installments of approximately $2.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Tranche B-4 Facility due on February 16, 2023. On April 17, 2018, the Company made an additional payment of $15.0 million, including $5.1 million on the Tranche B-3 Facility and $9.9 million on the Tranche B-4 Facility. On November 15, 2019, the Company made an additional payment of $20.0 million, including $7.0 million on the Tranche B-3 Facility and $13.0 million on the Tranche B-4 Facility.

Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $50.0 million of unrestricted and unencumbered cash to consolidated EBITDA). The Applicable Rate for the Pro Rata Facilities was 2.5% for Eurodollar Rate Loans and 1.5% for Base Rate Loans at December 31, 2020. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (based upon the LIBOR Rate prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. At December 31, 2020, the Pro Rata Facilities bore interest at a rate of LIBOR plus 2.5%. In addition, the Company is required to pay a commitment fee on undrawn amounts under the revolving line of credit.

The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated total leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. As of December 31, 2020, the Company was in compliance with such covenants.

Senior Notes

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year.

Redemption of 6.125% Senior Notes and 5.125% Senior Notes

On June 10, 2020, the Company issued conditional notices of full redemption providing for the redemption in full of the 6.125% Senior Notes and 5.125% Senior Notes on July 10, 2020 (the “Redemption Date”), in each case at a redemption price equal to 100.0% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but not including the Redemption Date (the “Redemption Price”). On June 24, 2020, the Company satisfied and discharged the indentures governing the 6.125% Senior Notes and the 5.125% Senior Notes by irrevocably depositing with a trustee sufficient funds equal to the Redemption Price for the 6.125% Senior Notes and the 5.125% Senior Notes and otherwise complying with the terms in the indentures relating to the satisfaction and discharge of the 6.125% Senior Notes and the 5.125% Senior Notes. In connection with the redemption of the 6.125% Senior Notes and the 5.125% Senior Notes, the Company recorded a debt extinguishment charge of $3.3 million, including the write-off of the deferred financing and other costs in the consolidated statements of operations.

5.625% Senior Notes due 2023

On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company has outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year.

6.500% Senior Notes due 2024

On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

Redemption of 5.265% Senior Notes and 6.500% Senior Notes

On January 29, 2021, the Company issued conditional notices of full redemption providing for the redemption in full of $650 million of 5.265% Senior Notes and $390 million of 6.500% Senior Notes to the holders of such notes. The redemption of this $1,040 million of additional debt, along with the payment of breakage costs of $6 million and estimated transaction costs of $9 million, is expected to be completed in early March 2021 and to be funded from cash from the balance sheet of $430 million and proceeds from a new senior secured credit facility of $625 million. The Company expects to enter into a new term loan and revolver as part of a five-year senior secured credit facility.

5.500% Senior Notes due 2028

On June 24, 2020, the Company issued $450.0 million of 5.500% Senior Notes due 2028 (the “5.500% Senior Notes”). The 5.500% Senior Notes mature on July 1, 2028 and bear interest at a rate of 5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021.

5.000% Senior Notes due 2029

On October 14, 2020, the Company issued $475.0 million of 5.000% Senior Notes due 2029 (the “5.000% Senior Notes”). The 5.000% Senior Notes mature on April 15, 2029 and bear interest at a rate of 5.000% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, commencing on April 15, 2021. The Company used the net proceeds of the 5.000% Senior Note to prepay approximately $453.3 million of the outstanding borrowings on our existing Tranche B-3 Facility and used the remaining net proceeds for general corporate purposes and to pay related fees and expenses in connection with the offering. In connection with the 5.000% Senior Notes, the Company recorded a debt extinguishment charge of $2.9 million, including the write-off of discount and deferred financing cost, which was recorded in debt extinguishment costs in the consolidated statements of operations.

The indentures governing the 5.625% Senior Notes, 6.500% Senior Notes, 5.500% Senior Notes and 5.000% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

9.0% and 9.5% Revenue Bonds

On November 11, 2012, in connection with the acquisition of The Pavilion at HealthPark, LLC (“Park Royal”), the Company assumed debt of $23.0 million. The fair market value of the debt assumed was $25.6 million and resulted in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (“9.0% and 9.5% Revenue Bonds”), respectively.

On December 1, 2018, the Company exercised the option to redeem in whole the 9.0% and 9.5% Revenue Bonds at a redemption price equal to the sum of 104% of the principal amount of the 9.0% and 9.5% Revenue Bonds plus accrued and unpaid interest. In connection with the redemption of the 9.0% and 9.5% Revenue Bonds, the Company recorded a debt extinguishment charge of $0.9 million, which was recorded in debt extinguishment costs in the consolidated statements of operations.

Debt Issuance Costs

Debt issuance costs are deferred and amortized to interest expense over the term of the related debt. Debt issuance costs at December 31, 2020 were $29.8 million, net of accumulated amortization of $56.0 million. Debt issuance costs at December 31, 2019 were $29.0 million, net of accumulated amortization of $46.2 million. Amortization expense related to debt issuance costs, which is included in interest expense on the consolidated statements of operations, was $9.8 million, $9.7 million and $9.0 million, respectively, for the years ended December 31, 2020, 2019 and 2018.

Other

The aggregate maturities of long-term debt at December 31, 2020 were as follows (in thousands):

2021	$	153,478
2022		284,282
2023		1,400,468
2024		390,000
2025		—
Thereafter		925,000
Total	$	3,153,228

Equity

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Equity

12. Equity

Preferred Stock

The Company’s amended and restated certificate of incorporation provides that up to 10,000,000 shares of preferred stock may be issued. The board of directors has the authority to issue preferred stock in one or more series and to fix for each series the voting powers (full, limited or none), and the designations, preferences and relative participating, optional or other special rights and qualifications, limitations or restrictions on the stock and the number of shares constituting any series and the designations of this series, without any further vote or action by the stockholders.

Common Stock

The Company’s amended and restated certificate of incorporation provides that up to 180,000,000 shares of common stock may be issued. Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters on which stockholders may vote. There are no preemptive, conversion, redemption or sinking fund provisions applicable to shares of the Company’s common stock. In the event of liquidation, dissolution or winding up, holders of the Company’s common stock are entitled to share ratably in the assets available for distribution, subject to any prior rights of any holders of preferred stock then outstanding. Delaware law prohibits the Company from paying any dividends unless it has capital surplus or net profits available for this purpose. In addition, the Amended and Restated Senior Credit Facility imposes restrictions on the Company’s ability to pay dividends.

Equity-Based Compensation

12 Months Ended

Dec. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

13. Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). At December 31, 2020, a maximum of 8,200,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 974,746 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the closing price of the Company’s common stock on the most recent trading date prior to the date of grant.

The Company recognized $22.5 million, $17.3 million and $22.0 million in equity-based compensation expense for the years ended December 31, 2020, 2019 and 2018, respectively. Stock compensation expense for the years ended December 31, 2020, 2019 and 2018 included forfeiture adjustments and restricted stock unit adjustments based on actual performance compared to vesting

targets of $0.5 million, $(6.4) million and $(5.5) million, respectively. At December 31, 2020, there was $36.9 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.2 years.

At December 31, 2020, there were no warrants outstanding. The Company recognized a deferred income tax benefit of $5.5 million, $4.0 million and $6.6 million for the years ended December 31, 2020, 2019 and 2018, respectively, related to equity-based compensation expense.

Stock Options

Stock option activity during 2018, 2019 and 2020 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2018		974,566		$	47.89		7.46	$	3,802
Options granted		374,700			37.54		9.21		246
Options exercised		(20,989	)		17.83	N/A			383
Options cancelled		(128,737	)		50.83	N/A		N/A
Options outstanding at December 31, 2018		1,199,540			44.64		7.26		2,717
Options granted		605,200			28.50		9.21		1,343
Options exercised		(55,671	)		19.05	N/A			658
Options cancelled		(389,001	)		40.84	N/A		N/A
Options outstanding at December 31, 2019		1,360,068			39.40		7.57		1,650
Options granted		507,600			33.13		9.18		157
Options exercised		(68,700	)		29.15	N/A			854
Options cancelled		(288,662	)		39.67	N/A		N/A
Options outstanding at December 31, 2020		1,510,306		$	37.56		7.35	$	1,414
Options exercisable at December 31, 2019		513,290		$	48.08		5.88	$	512
Options exercisable at December 31, 2020		596,606		$	45.37		5.55	$	543

Fair values are estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2020, 2019 and 2018:

	Year Ended December 31,
	2020			2019			2018
Weighted average grant-date fair value of options	$	12.37		$	17.59		$	13.67
Risk-free interest rate		1.6	%		2.4	%		2.2	%
Expected volatility		41	%		38	%		37	%
Expected life (in years)		5.0			5.0			5.1

The Company’s estimate of expected volatility for stock options is based upon the volatility of our stock price over the expected life of the award. The risk-free interest rate is the approximate yield on U. S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

Other Stock-Based Awards

Restricted stock activity during 2018, 2019 and 2020 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2018		809,868		$	50.19
Granted		480,137			36.84
Cancelled		(88,989	)		47.57
Vested		(395,959	)		50.41
Unvested at December 31, 2018		805,057		$	42.40
Granted		700,937			28.77
Cancelled		(389,684	)		33.50
Vested		(311,174	)		44.23
Unvested at December 31, 2019		805,136		$	34.14
Granted		637,312			25.82
Cancelled		(129,683	)		34.56
Vested		(289,769	)		35.88
Unvested at December 31, 2020		1,022,996		$	28.41

Restricted stock unit activity during 2018, 2019 and 2020 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2017		360,909		$	50.04
Granted		285,358			42.26
Cancelled		(89,173	)		55.44
Vested		(72,983	)		49.64
Unvested at December 31, 2018		484,111		$	44.52
Granted		234,408			34.54
Cancelled		(271,162	)		45.17
Vested		—			—
Unvested at December 31, 2019		447,357		$	38.89
Granted		583,680			10.60
Performance adjustment		117,772			13.50
Cancelled		(63,056	)		43.35
Vested		(12,691	)		42.09
Unvested at December 31, 2020		1,073,062		$	20.15

Restricted stock awards are time-based vesting awards that vest over a period of three or four years and are subject to continuing service of the employee or non-employee director over the ratable vesting periods. The fair values of the restricted stock awards were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date.

Restricted stock units are granted to employees and are subject to Company performance compared to pre-established targets and Company performance compared to peers. In addition to Company performance, these performance-based restricted stock units are subject to the continuing service of the employee during the two- or three-year period covered by the awards. The performance condition for the restricted stock units is based on the Company’s achievement of annually established targets for diluted earnings per share. Additionally, the number of shares issuable pursuant to restricted stock units granted during 2020 and 2019 are subject to adjustment based on the Company’s three-year annualized total stockholder return relative to a peer group consisting of S&P 1500 companies within the Healthcare Providers & Services 6 digit GICS industry group and selected other companies deemed to be peers. The number of shares issuable at the end of the applicable vesting period of restricted stock units ranges from 0% to 200% of the targeted units based on the Company’s actual performance compared to the targets and, for 2020 and 2019 awards, performance compared to peers.

The fair values of restricted stock units were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at its Monte-Carlo simulation value for units subject to market conditions.

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

14. Income Taxes

Provision for income taxes consists of the following for the periods presented (in thousands):

	Year Ended December 31,
	2020			2019			2018
Current:
Federal	$	(18,215	)	$	18,954		$	13,962
State		4,981			3,440			1,113
Foreign		732			1,602			1,569
Total current		(12,502	)		23,996			16,644
Deferred:
Federal		46,442			(1,572	)		(7,176	)
State		564			2,509			(10	)
Foreign		6,102			152			449
Total deferred provision		53,108			1,089			(6,737	)
Provision for income taxes	$	40,606		$	25,085		$	9,907

A reconciliation of the U.S. federal statutory rate to the effective tax rate is as follows for the periods presented:

	Year Ended December 31,
	2020			2019			2018
U.S. federal statutory rate on income before income taxes		21.0	%		21.0	%		21.0	%
Impact of foreign operations		(0.5	)		1.1			0.6
Effects of statutory rate change		3.2			—			—
Impacts of SAB 118		—			—			(16.4	)
State income taxes, net of federal tax effect		5.1			5.8			3.4
Permanent differences		1.5			3.3			9.2
Change in valuation allowance		127.4			0.6			(0.3	)
Unrecognized tax benefit release		(0.4	)		0.5			(0.9	)
Federal tax credits		(1.0	)		(2.2	)		(2.3	)
Basis recognition related to foreign divestiture		(129.9	)		—			—
CARES Act impacts to net operating losses		(4.5	)		—			—
Other		0.2			1.9			0.4
Effective income tax rate		22.1	%		32.0	%		14.7	%

For the year ended December 31, 2020, the provision for income taxes was $40.6 million, reflecting an effective tax rate of 22.1%, compared to $25.1 million, reflecting an effective tax rate of 32.0%, for the year ended December 31, 2019. The decrease in the effective tax rate for the year ended December 31, 2020 was primarily attributable to the release of a state valuation allowance and permanent benefits generated from the application of federal net operating loss carryback provisions within the CARES Act. The federal net operating loss legislation within the CARES Act allows net operating losses generated in tax years 2018 through 2020 to be carried back at a 35% tax rate to offset income in tax years prior to 2018 (21% for tax years after 2017), resulting in a permanent benefit.

The domestic and foreign components of income from continuing operations before income taxes for continuing operations are as follows (in thousands):

	Year Ended December 31,
	2020		2019		2018
Foreign	$	9,904	$	6,070	$	9,947
Domestic		173,893		72,325		57,448
Income from continuing operations before income taxes	$	183,797	$	78,395	$	67,395

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities of the Company at December 31, 2020 and December 31, 2019 were as follows (in thousands):

	December 31,
	2020			2019
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$	7,682		$	9,913
Bad debt allowance		1,243			996
Accrued compensation and severance		20,889			14,241
Insurance reserves		18,497			16,485
Leases		846			800
Accrued expenses		11,817			1,020
Interest carryforwards		3,374			40,792
Lease right-of-use liabilities		24,402			26,375
Fixed asset basis difference		—			14,714
Basis in foreign subsidiary		239,073			—
Other assets		13,251			2,777
Total gross deferred tax assets		341,074			128,113
Less: valuation allowance		(241,225	)		(6,859	)
Deferred tax assets		99,849			121,254
Deferred tax liabilities:
Fixed asset basis difference		(5,553	)		—
Prepaid items		(2,960	)		(2,163	)
Intangible assets		(115,196	)		(100,881	)
Lease right-of-use assets		(22,948	)		(24,898	)
Other liabilities		—			(12,793	)
Total deferred tax liabilities		(146,657	)		(140,735	)
Total net deferred tax liability	$	(46,808	)	$	(19,481	)

The Company has established a deferred tax asset related to the Company’s investment in a foreign subsidiary in the amount of $239.1 million, resulting from the divestiture of the U.K. business. This deferred tax asset was not recognized in prior years under the exception within ASC 740-30-25-9 that limits the recognition of deferred tax assets for the excess of tax basis over book basis in an investment in a subsidiary to only instances when it is apparent that the difference will reverse in the foreseeable future. As a result of the divestiture of the U.K. business, and the classification of the U.K. business as discontinued operations during the year, the Company no longer meets this exception and accordingly recognized the deferred tax asset as a component of income tax expense. Further, as this deferred tax asset is expected to result in a capital loss upon the finalization of the divestiture, the Company has concluded a full valuation allowance of $239.1 million is necessary due to the limitations in realizing the asset via offsetting capital gains in the future. The recognition of the valuation allowance on this deferred tax asset has also been recognized as a component of income tax expense.

As of December 31, 2020, no deferred taxes have been provided on the accumulated undistributed earnings of our continuing foreign operations within Puerto Rico. An actual repatriation of earnings from our foreign operations could still be subject to additional foreign withholding and U.S. state taxes. Based upon evaluation of our foreign operations, undistributed earnings are intended to remain permanently reinvested to finance anticipated future growth and expansion, and accordingly, deferred taxes have not been recorded. If undistributed earnings of our foreign operations were not considered permanently reinvested as of December 31, 2020, an immaterial amount of additional deferred taxes would have been recorded. Our foreign subsidiary in Puerto Rico has been granted a tax exemption for which a tax credit of up to 15% of eligible payroll expenses is available to offset up to 50% of the income taxes attributed to that entity. The impact of this tax exemption is not material to the tax provision.

The Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. At December 31, 2020 and 2019, the Company carried a valuation allowance against deferred tax assets of $241.2 million and $6.9 million, respectively. These amounts are primarily related to deferred tax assets related to the Company’s investment in a foreign subsidiary and certain state net operating losses.

As of December 31, 2020 and 2019, the Company had no federal net operating loss carryforwards. The foreign net operating loss carryforwards at December 31, 2020 and 2019 are approximately $0.1 million and $0.1 million, respectively, and have no expiration.

The Company has state net operating loss carryforwards at December 31, 2020 and 2019 of approximately $170.0 million and $220.8 million, respectively. These net operating loss carryforwards, if not used to offset future taxable income, will expire from 2022 to 2035. In addition, the Company has certain state tax credits of $0.6 million which will begin to expire in 2030 if not utilized.

Income taxes receivable was $0.9 million and $4.8 million at December 31, 2020 and 2019, respectively, and was included in other current assets in the consolidated balance sheets. Income taxes payable of $16.3 million at December 31, 2020 was included in other accrued liabilities in the consolidated balance sheets.

The Company recorded income taxes payable related to unrecognized tax benefits of $2.5 million and $3.1 million at December 31, 2020 and December 31, 2019, respectively. These amounts are inclusive of any interest and penalties, which is included in other liabilities on the consolidated balance sheets. A reconciliation of the beginning and ending amount of unrecognized income tax benefits, net of the federal benefit, is as follows (in thousands):

	2020			2019
Balance at January 1	$	2,441		$	713
Additions based on tax positions related to the current year		—			3,001
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities		(381	)		(1,273	)
Balance at December 31	$	2,060		$	2,441

At December 31, 2020 and 2019, the cumulative amounts of interest and penalties recognized were $0.5 million and $0.6 million, respectively. Unrecognized tax benefits of $0.4 million would affect the effective rate if recognized. It is possible the amount of unrecognized tax benefit could change in the next twelve months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, management does not anticipate the change will have a material impact on the Company’s consolidated financial statements.

The Company’s uncertain tax positions are related to tax years that remain subject to examination by the relevant taxing authorities. The Company and its subsidiaries file income tax returns in federal and in many state and local jurisdictions as well as foreign jurisdictions. The Company may be subject to examination by the Internal Revenue Service (“IRS”) for calendar year 2017 through 2019. Additionally, any net operating losses that were generated in prior years and utilized in these years may also be subject to examination by the IRS. While no other foreign jurisdictions are presently under examination, the Company may be subject to examination for calendar years 2016 through 2019. Generally, for state tax purposes, the Company’s 2014 through 2019 tax years remain open for examination by the tax authorities. At the date of this report there were no audits or inquires that had progressed sufficiently to predict their ultimate outcome.

On December 22, 2017, Public Law 115-97, informally referred to as The Tax Cuts and Jobs Act (the “Tax Act”) was enacted into law. The Tax Act provided for significant changes to the U.S. tax code that has impacted businesses. ASC 740 “Income Taxes” (“ASC 740”) requires the Company to recognize the effect of tax law changes in the period of enactment. However, the SEC staff issued Staff Accounting Bulletin 118 (“SAB 118”) which allowed the Company to record provisional amounts during a measurement period similar to the measurement period used when accounting for business combinations. As part of the analysis of the Tax Act, the Company made an adjustment regarding the treatment of foreign dividends of $10.9 million during the year ended December 31, 2018, impacting the effective tax rate.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Derivatives

12 Months Ended

Dec. 31, 2020

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivatives

15. Derivatives

The Company entered into foreign currency forward contracts during the years ended December 31, 2020 and 2019 in connection with certain transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. Foreign currency forward contracts limit the economic risk of changes in the exchange rate between US Dollars (“USD”) and British Pounds (“GBP”) associated with cash transfers.

In May 2016, the Company entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate GBP-denominated debt of £449.3 million. In August 2019, the Company terminated its existing net investment cross currency swap derivatives of $105.0 million. Cash received from the termination of the cross currency swap derivatives is included in investing activities in the consolidated statements of cash flows. The related gain from this termination is included in accumulated other comprehensive loss in accordance with ASC 815-30-40-1.

In August 2019, the Company also entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate GBP-denominated debt of £538.1 million. During the term of the swap agreements, the Company will receive semi-annual interest payments in USD from the counterparties at fixed interest rates, and the Company will make semi-annual interest payments in GBP to the counterparties at fixed interest rates. The interest payments under the cross-currency swap agreements result in £25.4 million of annual cash flows from the Company’s U.K. business being converted to $35.8 million.

The Company has designated the cross currency swap agreements and certain forward contracts entered into during 2019 and 2020 as qualifying hedging instruments and is accounting for these as net investment hedges. The fair values of these derivatives at December 31, 2020 and 2019 of $84.6 million and $68.9 million, respectively, are recorded as derivative instrument liabilities and noncurrent derivative instrument liabilities, respectively, on the consolidated balance sheets. During the year ended 2020, the Company elected the spot method for recording its net investment hedges. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense on the consolidated statements of operations. Gains and losses resulting from fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive loss as the swaps are effective in hedging the designated risk. Cash flows related to the cross currency swap derivatives are included in operating activities in the consolidated statements of cash flows.

In conjunction with the U.K. Sale in January 2021, the Company settled its cross currency swap liability and outstanding forward contracts.

Fair Value Measurements

12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

16. Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 5.500% Senior Notes, 5.000% Senior Notes, other long-term debt and derivative instruments at December 31, 2020 and 2019 were as follows (in thousands):

	Carrying Amount				Fair Value
	December 31,				December 31,
	2020		2019		2020		2019
Amended and Restated Senior Credit Facility	$	1,175,437	$	1,668,062	$	1,175,437	$	1,668,062
6.125% Senior Notes due 2021	$	—	$	149,254	$	—	$	149,441
5.125% Senior Notes due 2022	$	—	$	297,761	$	—	$	299,994
5.625% Senior Notes due 2023	$	646,344	$	644,771	$	647,960	$	655,249
6.500% Senior Notes due 2024	$	385,636	$	384,430	$	393,850	$	398,366
5.500% Senior Notes due 2028	$	443,139	$	—	$	475,931	$	—
5.000% Senior Notes due 2029	$	468,245	$	—	$	499,852	$	—
Other long-term debt	$	3,625	$	4,821	$	3,625	$	4,821
Derivative instruments	$	84,584	$	68,915	$	84,584	$	68,915

The Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 5.500% Senior Notes, 5.000% Senior Notes and other long-term debt were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

The fair values of the derivative instruments were categorized as Level 2 in the GAAP fair value hierarchy and were based on observable market inputs including applicable exchange rates and interest rates.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

17. Commitments and Contingencies

The Company is, from time to time, subject to various claims, lawsuits, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Certain of the Company’s individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations, and violations of the False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the federal False Claims Act permits private parties to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions.

On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled St. Clair County Employees’ Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988, which is pending in the United States District Court for the Middle District of Tennessee. The complaint purports to be brought on behalf of a class consisting of all persons (other than defendants) who purchased securities of the Company between April 30, 2014 and November 15, 2018, and alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. At this time, we are not able to quantify any potential liability in connection with this litigation because the case is in its early stages.

On February 21, 2019, a purported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Davydov v. Joey A. Jacobs, et al., Case No. 3:19-cv-00167, which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Section 10(b) and 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On May 23, 2019, a purported stockholder filed a second related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Beard v. Jacobs, et al., Case No. 3:19-cv-0441, which is pending the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Sections 10(b), 14(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and insider selling. On June 11, 2019, the Davydov and Beard actions were consolidated. On February 16, 2021, the parties filed a stipulation staying the case. On October 23, 2020, a purported stockholder filed a third related derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled Pfenning v. Jacobs, et al., Case No. 2020-0915-JRS, which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty. On February 17, 2021, the court entered an order staying the case. At this time, we are not able to quantify any potential liability in connection with this litigation because the cases are in their early stages.

On April 25, 2018, plaintiff filed Pence v. Sober Living By the Sea, Inc. - 30-2018-00988742-CU-OE-CXC, Orange County Superior Court (Pence I). On July 13, 2018, plaintiff next filed Pence v. Sober Living by the Sea, Inc.; Acadia Healthcare Company, Inc. - 30-2018-01005317-CU-OE-CJC, Orange County Superior Court (Pence II). These cases have now been consolidated before the same judge in the Complex Litigation Department of the Orange County Superior Court. The complaints allege various wage and hour violations under California law on behalf of a putative class of all non-exempt California employees of Acadia and various subsidiaries, going back to April 25, 2014, and on behalf of purportedly aggrieved non-exempt employees under California’s Private Attorney General Act (“PAGA”). The claims include (1) failure to provide overtime wages; (2); failure to provide minimum wages; (3) failure to provide meal periods; (4) failure to provide rest periods; (5); failure to pay wages due at termination; (6) failure to provide accurate wage statements; (7) violations of California Business and Professions Code section 17200; and (8) civil penalties under California Labor Code section 2699 (PAGA). During the second quarter of 2020, the Company recorded approximately $4.0 million to transaction-related expenses in the consolidated statements of operations based on the Company’s expected settlement and legal fees.

In the fall of 2017, the Office of Inspector General (“OIG”) issued subpoenas to three of the Company’s facilities requesting certain documents from January 2013 to the date of the subpoenas. The U.S. Attorney’s Office for the Middle District of Florida issued a civil investigative demand to one of the Company’s facilities in December 2017 requesting certain documents from November 2012 to the date of the demand. In April 2019, the OIG issued subpoenas relating to six additional facilities requesting certain documents and information from January 2013 to the date of the subpoenas. The government’s investigation of each of these facilities is focused on claims not eligible for payment because of alleged violations of certain regulatory requirements relating to, among other things, medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company is cooperating with the government’s investigation but is not able to quantify any potential liability in connection with these investigations.

Noncontrolling Interests

12 Months Ended

Dec. 31, 2020

Noncontrolling Interest [Abstract]

Noncontrolling Interests

18. Noncontrolling Interests

Noncontrolling interests in the consolidated financial statements represents the portion of equity held by noncontrolling partners in the Company’s non-wholly owned subsidiaries. At December 31, 2020, the Company operated six facilities through non-wholly owned subsidiaries. The Company owns between approximately 60% and 86% of the equity interests of these entities and noncontrolling partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions, and the Company consolidates the operations of each facility based on its equity ownership and its control of the entity. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at January 1, 2019	$	28,806
Acquisition of redeemable noncontrolling interests		3,300
Net income attributable to noncontrolling interests		1,199
Distributions to noncontrolling interests		(154	)
Balance at December 31, 2019		33,151
Acquisition of redeemable noncontrolling interests		20,147
Net income attributable to noncontrolling interests		2,933
Distributions to noncontrolling interests		(916	)
Balance at December 31, 2020	$	55,315

Employee Benefit Plans

12 Months Ended

Dec. 31, 2020

Compensation And Retirement Disclosure [Abstract]

Employee Benefit Plans

19. Employee Benefit Plans

The Company maintains a qualified defined contribution 401(k) plan covering substantially all of its employees in the U.S. The Company may, at its discretion, make contributions to the plan. The Company recorded expense of $3.8 million, $4.1 million, and $3.5 million related to the 401(k) plan for the years ended December 31, 2020, 2019 and 2018, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

+ Details

Accumulated Other Comprehensive Loss

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Accumulated Other Comprehensive Loss

20. Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments			Pension Plan			Total
Balance at January 1, 2018	$	(376,740	)	$	7,167		$	(4,545	)	$	(374,118	)
Foreign currency translation (loss) gain		(127,788	)		—			267			(127,521	)
Gain on derivative instruments, net of tax of $12.7 million		—			36,799			—			36,799
Pension liability adjustment, net of tax of $0.3 million		—			—			2,463			2,463
Balance at December 31, 2018		(504,528	)		43,966			(1,815	)		(462,377	)
Foreign currency translation gain (loss)		69,895			—			(84	)		69,811
Loss on derivative instruments, net of tax of $(3.6) million		—			(19,008	)		—			(19,008	)
Pension liability adjustment, net of tax of $(0.6) million		—			—			(3,310	)		(3,310	)
Balance at December 31, 2019		(434,633	)		24,958			(5,209	)		(414,884	)
Foreign currency translation gain (loss)		61,532			—			(285	)		61,247
Loss on derivative instruments, net of tax of $(3.9) million		—			(11,272	)		—			(11,272	)
Pension liability adjustment, net of tax of $(0.8) million		—			—			(6,456	)		(6,456	)
Balance at December 31, 2020	$	(373,101	)	$	13,686		$	(11,950	)	$	(371,365	)

Quarterly Information (Unaudited)

12 Months Ended

Dec. 31, 2020

Quarterly Financial Information Disclosure [Abstract]

Quarterly Information (Unaudited)

21. Quarterly Information (Unaudited)

The tables below present summarized unaudited quarterly results of operations for the years ended December 31, 2020 and 2019. Management believes that all necessary adjustments have been included in the amounts stated below for a fair presentation of the results of operations for the periods presented when read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2020 and 2019. Results of operations for a particular quarter are not necessarily indicative of results of operations for an annual period and are not predictive of future periods.

	Quarter Ended
	March 31,		June 30,		September 30,			December 31,
	(In thousands except per share amounts)
2020:
Revenue	$	509,217	$	491,475	$	547,961		$	541,276
Income from continuing operations, net of taxes	$	21,251	$	30,721	$	45,063		$	46,156
Income (loss) from discontinued operations, net of taxes	$	12,816	$	10,993	$	(7,502	)	$	(828,697	)	⁽¹⁾
Net income (loss) attributable to Acadia Healthcare Company, Inc. stockholders	$	33,463	$	41,079	$	36,998		$	(783,672	)	⁽¹⁾
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	0.24	$	0.34	$	0.51		$	0.51
Income (loss) from discontinued operations	$	0.14	$	0.13	$	(0.09	)	$	(9.42	)	⁽¹⁾
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	0.38	$	0.47	$	0.42		$	(8.91	)	⁽¹⁾
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	0.23	$	0.34	$	0.50		$	0.50
Income (loss) from discontinued operations	$	0.15	$	0.12	$	(0.08	)	$	(9.28	)	⁽¹⁾
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	0.38	$	0.46	$	0.42		$	(8.78	)	⁽¹⁾

2019:
Revenue	$	487,960	$	509,813	$	509,383		$	501,225
Income (loss) from continuing operations, net of taxes	$	13,618	$	26,964	$	24,920		$	(12,192	)	⁽²⁾
Income from discontinued operations, net of taxes	$	15,893	$	21,237	$	17,803		$	1,879		⁽²⁾
Net income (loss) attributable to Acadia Healthcare Company, Inc. stockholders	$	29,471	$	48,140	$	42,566		$	(11,254	)	⁽²⁾
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income (loss) from continuing operations attributable to Acadia Healthcare Company, Inc.	$	0.16	$	0.31	$	0.28		$	(0.15	)	⁽²⁾
Income from discontinued operations	$	0.18	$	0.24	$	0.21		$	0.02		⁽²⁾
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	0.34	$	0.55	$	0.49		$	(0.13	)	⁽²⁾
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income (loss) from continuing operations attributable to Acadia Healthcare Company, Inc.	$	0.15	$	0.31	$	0.28		$	(0.15	)	⁽²⁾
Income from discontinued operations	$	0.19	$	0.24	$	0.20		$	0.02		⁽²⁾
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	0.34	$	0.55	$	0.48		$	(0.13	)	⁽²⁾

(1)	Includes U.K. loss on sale of $867.3 million which includes approximately $356.2 million of non-cash goodwill impairment.

(2)	Includes loss on impairment of $27.2 million in continuing operations and $27.2 million in discontinued operations.

Financial Information for the Company and Its Subsidiaries

12 Months Ended

Dec. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Financial Information for the Company and Its Subsidiaries

22. Financial Information for the Company and Its Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 5.500% Senior Notes and 5.000% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Summarized financial information presented below is consistent with the consolidated financial statements of the Company, except transactions between combining entities have been eliminated. Financial information for the combined non-guarantor entities has been excluded. Presented below is consolidated financial information for Acadia Healthcare Company, Inc. and the combined wholly-owned subsidiary guarantors at December 31, 2020 and 2019, and for the December 31, 2020.

Summarized balance sheet information (in thousands):

	December 31,
	2020		2019
Current assets	$	654,735	$	421,653
Property and equipment, net		1,421,875		1,313,830
Goodwill		1,992,305		1,992,344
Total noncurrent assets		3,640,809		3,516,967

Current liabilities		626,419		305,131
Long-term debt		2,786,125		2,877,602
Total noncurrent liabilities		3,045,981		3,159,489
Redeemable noncontrolling interests		—		—
Total equity		623,144		474,000

Summarized operating results information (in thousands):

	For the Year Ended December 31, 2020
Revenue	$	1,943,734
Income from continuing operations before income taxes		161,293
Net loss		(269,231	)
Net loss attributable to Acadia Healthcare Company, Inc.		(269,231	)

Subsequent Events

12 Months Ended

Dec. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

23. Subsequent Events

On January 19, 2021, the Company completed the U.K. Sale pursuant to a Share Purchase Agreement in which it sold all of the securities of AHC-WW Jersey Limited, a private limited liability company incorporated in Jersey and a subsidiary of the Company, which constitutes the entirety of our U.K. business operations. The U.K. Sale resulted in approximately $1,525 million of gross proceeds before deducting the settlement of existing foreign currency hedging liabilities of $85 million based on the current GBP to USD exchange rate, cash retained by the buyer of approximately $75 million and transaction costs of $16 million. The Company used the net proceeds of $1,425 million (or $1,350 million, net of cash retained by the buyer) to repay in full the outstanding balances of its TLA Facility of $312 million and its Tranche B-4 Facility of $768 million of the Amended and Restated Credit Agreement and added $345 million of cash to the balance sheet. In addition to reducing its indebtedness, the U.K. Sale allows the Company to focus on U.S. operations. As a result of the U.K. Sale, the Company reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements.

On January 29, 2021, the Company issued conditional notices of full redemption proving for the redemption in full of $650 million of 5.265% Senior Notes and $390 million of 6.500% Senior Notes to the holders of such notes. The redemption of this $1,040 million of additional debt, along with the payment of breakage costs of $6 million and estimated transaction costs of $9 million, is expected to be completed in early March 2021 and to be funded from cash from the balance sheet of $430 million and proceeds from a new senior secured credit facility of $625 million. The Company expects to enter into a new term loan and revolver as part of a five-year senior secured credit facility.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Cash and Cash Equivalents

Insurance

Property and Equipment and Other Long-Lived Assets

Goodwill and Indefinite-Lived Intangible Assets

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2020		2019
Prepaid expenses	$	19,480	$	17,343
Workers’ compensation deposits – current portion		12,000		10,000
Other receivables		10,025		10,661
Insurance receivable – current portion		6,792		3,030
Cost report receivable		5,818		13,723
Inventory		4,851		4,075
Income taxes receivable		897		4,786
Other		1,469		1,349
Other current assets	$	61,332	$	64,967

Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2020		2019
Accrued interest	$	40,479	$	33,323
Unearned income		35,946		1,895
Finance lease liabilities		32,188		3,765
Accrued expenses		28,452		18,595
Income taxes payable		16,345		—
Insurance liability – current portion		9,700		4,731
Accrued property taxes		6,763		4,755
Government relief funds		5,495		—
Other		3,085		2,170
Other accrued liabilities	$	178,453	$	69,234

Stock Compensation

Earnings Per Share

Income Taxes

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2020		2019
Prepaid expenses	$	19,480	$	17,343
Workers’ compensation deposits – current portion		12,000		10,000
Other receivables		10,025		10,661
Insurance receivable – current portion		6,792		3,030
Cost report receivable		5,818		13,723
Inventory		4,851		4,075
Income taxes receivable		897		4,786
Other		1,469		1,349
Other current assets	$	61,332	$	64,967

Summary of Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2020		2019
Accrued interest	$	40,479	$	33,323
Unearned income		35,946		1,895
Finance lease liabilities		32,188		3,765
Accrued expenses		28,452		18,595
Income taxes payable		16,345		—
Insurance liability – current portion		9,700		4,731
Accrued property taxes		6,763		4,755
Government relief funds		5,495		—
Other		3,085		2,170
Other accrued liabilities	$	178,453	$	69,234

U.K. Sale (Tables)

12 Months Ended

Dec. 31, 2020

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Financial Condition, Results of Operations and Cash Flows of U.K. Operations as Discontinued Operations

For the years ended December 31, 2020, 2019 and 2018, results of operations of the U.K. operations were as follows (in thousands):

	Year Ended December 31,
	2020			2019			2018
Revenue	$	1,119,768		$	1,099,081		$	1,107,747
Salaries, wages and benefits		632,134			609,823			610,031
Professional fees		127,291			122,532			117,376
Supplies		38,285			37,527			37,852
Rents and leases		47,748			46,743			45,967
Other operating expenses		113,534			115,897			110,827
Depreciation and amortization		74,935			76,121			78,490
Interest expense, net		(417	)		(231	)		876
Loss on sale		867,324			—			—
Loss on impairment		20,239			27,169			337,889
Transaction-related expenses		8,719			5,907			4,788
Total expenses		1,929,792			1,041,488			1,344,096
(Loss) income from discontinued operations before income taxes		(810,024	)		57,593			(236,349	)
Provision for (benefit from) income taxes		2,366			781			(3,375	)
(Loss) income from discontinued operations	$	(812,390	)	$	56,812		$	(232,974	)

The major classes of assets and liabilities for the U.K. operations are shown below (in thousands):

	December 31,
	2020		2019

Cash and cash equivalents	$	75,051	$	24,657
Accounts receivable, net		52,196		50,912
Other current assets		13,361		13,277
Current assets of discontinued operations		140,608		88,846
Property and equipment, net		1,297,923		1,724,447
Goodwill		—		364,027
Intangible assets, net		22,289		21,531
Operating lease right-of-use assets		341,289		404,042
Other assets		7,706		13,127
Total assets of discontinued operations		1,809,815		2,616,020

Current liabilities:
Accounts payable	$	44,929	$	36,788
Current portion of operating lease liabilities		11,141		11,021
Other current liabilities		136,895		100,883
Current liabilities of discontinued operations		192,965		148,692
Operating lease liabilities		387,607		416,609
Deferred tax liabilities		57,230		49,040
Other liabilities		22,225		21,435
Total liabilities of discontinued operations	$	660,027	$	635,776

U.K. Sales [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Summary of Funded Status (Unfunded Liability)

	2020		2019
Projected benefit obligation	$	80,158	$	66,468
Fair value of plan assets		71,979		62,207
Unfunded liability	$	8,179	$	4,261

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Revenue (Tables)

12 Months Ended

Dec. 31, 2020

Revenue From Contract With Customer [Abstract]

Schedule of Revenue Attributed to Each Category

The table below presents total U.S. revenue attributed to each category (in thousands):

	Year Ended December 31,
	2020		2019		2018
Acute inpatient psychiatric facilities	$	984,609	$	912,097	$	814,124
Specialty treatment facilities		802,022		788,232		761,017
Residential treatment centers		281,158		286,959		293,053
Outpatient community-based facilities		22,140		21,093		36,501
Revenue	$	2,089,929	$	2,008,381	$	1,904,695

Schedule of Revenue and Percentage Generated by Each Payor Type in U.S Facilities

The following table presents revenue by payor type and as a percentage of revenue in our U.S. Facilities for the years ended December 31, 2020, 2019 and 2018 (in thousands):

	Year Ended December 31,
	2020					2019					2018
	Amount		%			Amount		%			Amount		%
Commercial	$	596,698		28.5	%	$	565,350		28.2	%	$	573,089		30.1	%
Medicare		330,070		15.8	%		294,691		14.7	%		280,340		14.7	%
Medicaid		1,037,852		49.7	%		1,007,102		50.1	%		893,644		46.9	%
Self-Pay		98,302		4.7	%		118,716		5.9	%		134,054		7.1	%
Other		27,007		1.3	%		22,522		1.1	%		23,568		1.2	%
Revenue	$	2,089,929		100.0	%	$	2,008,381		100.0	%	$	1,904,695		100.0	%

Summary of the Activity in Unearned Revenue in U.S. Facilities

A summary of the activity in unearned revenue in the U.S. Facilities is as follows (in thousands):

Balance at December 31, 2019	$	1,895
Payments received		51,044
Revenue recognized		(5,743	)
Balance at December 31, 2020	$	47,196

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2020, 2019 and 2018 (in thousands, except per share amounts):

	Year Ended December 31,
	2020			2019		2018
Numerator:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	140,258		$	52,111	$	57,224
(Loss) income from discontinued operations		(812,390	)		56,812		(232,974	)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	(672,132	)	$	108,923	$	(175,750	)
Denominator:
Weighted average shares outstanding for basic earnings per share		87,875			87,612		87,288
Effects of dilutive instruments		720			204		127
Shares used in computing diluted earnings per common share		88,595			87,816		87,415

Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	1.60		$	0.59	$	0.66
(Loss) income from discontinued operations		(9.25	)		0.65		(2.67	)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	(7.65	)	$	1.24	$	(2.01	)

Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	1.58		$	0.59	$	0.65
(Loss) income from discontinued operations		(9.17	)		0.65		(2.66	)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	(7.59	)	$	1.24	$	(2.01	)

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2020

Business Combinations [Abstract]

Summary of Changes in Goodwill

The following table summarizes changes in goodwill for the years 2019 and 2020 (in thousands):

Balance at January 1, 2019	$	2,044,837
Increase from contribution of redeemable noncontrolling interests		3,300
Increase from 2019 acquisitions		36,967
Goodwill at December 31, 2019		2,085,104
Increase from contribution of redeemable noncontrolling interests		20,200
Adjustments related to 2019 acquisitions		(40	)
Goodwill at December 31, 2020	$	2,105,264

	Year Ended December 31,
	2020		2019		2018
Legal, accounting and other acquisition-related costs	$	8,252	$	3,030	$	3,152
Termination, restructuring and strategic review costs		3,468		12,598		12,534
Management transition costs		—		5,529		14,033
	$	11,720	$	21,157	$	29,719

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2020

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consisted of the following at December 31, 2020 and 2019 (in thousands):

	December 31,
	2020			2019
Land	$	144,221		$	138,325
Building and improvements		1,490,149			1,275,610
Equipment		220,690			199,264
Construction in progress		217,479			247,467
		2,072,539			1,860,666
Less: accumulated depreciation		(449,643	)		(361,079	)
Property and equipment, net	$	1,622,896		$	1,499,587

Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Other Identifiable Intangible Assets and Related Accumulated Amortization

Other identifiable intangible assets and related accumulated amortization consisted of the following at December 31, 2020 and 2019 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	December 31, 2020		December 31, 2019		December 31, 2020			December 31, 2019
Intangible assets subject to amortization:
Contract intangible assets	$	—	$	2,100	$	—		$	(2,100	)
Non-compete agreements		1,131		1,131		(1,131	)		(1,131	)
		1,131		3,231		(1,131	)		(3,231	)
Intangible assets not subject to amortization:
Licenses and accreditations		11,873		12,020		—			—
Trade names		39,526		39,735		—			—
Certificates of need		17,136		17,071		—			—
		68,535		68,826		—			—
Total	$	69,666	$	72,057	$	(1,131	)	$	(3,231	)

Leases (Tables)

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Schedule of Leases on Consolidated Balance Sheet

The Company recorded the following at December 31, 2020 and 2019 on the consolidated balance sheet (in thousands):

Right-of-Use Assets	Balance Sheet Classification	December 31, 2020		December 31, 2019
Finance lease right-of-use assets	Property and equipment, net	$	34,621	$	35,489
Operating lease right-of-use assets	Operating lease right-of-use assets		96,937		97,795
Total		$	131,558	$	133,284

Lease Liabilities	Balance Sheet Classification	December 31, 2020		December 31, 2019
Current:
Finance lease liabilities	Other accrued liabilities	$	32,188	$	3,765
Operating lease liabilities	Current portion of operating lease liabilities		18,916		18,119
Noncurrent:
Finance lease liabilities	Other liabilities		10,744		39,719
Operating lease liabilities	Operating lease liabilities		84,029		85,643
Total		$	145,877	$	147,246

Schedule of Weighted-average Remaining Lease Terms and Discount Rates

Weighted-average remaining lease terms and discount rates were as follows at December 31, 2020 and 2019:

	December 31,
	2020			2019
Weighted-average remaining lease term (in years):
Finance	6.7			6.5
Operating	8.5			8.6

Weighted-average discount rate:
Finance		5.9	%		5.3	%
Operating		6.5	%		6.5	%

Schedule of Lease Cost

The Company recorded the following lease costs at December 31, 2020 and 2019 (in thousands):

	December 31,
	2020		2019
Finance lease costs:
Depreciation of leased assets		868		907
Interest of lease liabilities		3,214		3,226
Total finance lease costs	$	4,082	$	4,133

Operating lease costs		27,050		25,630
Variable lease costs		2,501		1,966
Short term lease costs		3,558		4,790
Other lease costs		4,253		3,101
Total rents and leases	$	37,362	$	35,487

Total lease costs	$	41,444	$	39,620

Schedule of Undiscounted Cash Flows for Finance and Operating Leases

Undiscounted cash flows for finance and operating leases recorded on the consolidated balance sheet were as follows at December 31, 2020 (in thousands):

	Finance Leases		Operating Leases
2021	$	32,909	$	25,015
2022		990		21,032
2023		990		17,336
2024		1,007		14,832
2025		1,089		12,101
Thereafter		23,999		52,866
Total minimum lease payments		60,984		143,182
Less: amount of lease payments representing interest		18,052		40,237
Present value of future minimum lease payments		42,932		102,945
Less: Current portion of lease liabilities		32,188		18,916
Noncurrent lease liabilities	$	10,744	$	84,029

Schedule of Supplemental Data

Supplemental data for the years ended December 31, 2020 and 2019 were as follows (in thousands):

	December 31,
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	26,810	$	25,086
Operating cash flows for finance leases	$	3,214	$	3,226
Financing cash flows for finance leases	$	551	$	862

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	21,285	$	21,809
Finance leases	$	-	$	-

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Components of Long-Term Debt

Long-term debt consisted of the following (in thousands):

	December 31,
	2020			2019
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loan	$	311,733		$	346,750
Senior Secured Term B Loans		872,870			1,338,928
Senior Secured Revolving Line of Credit		—			—
6.125% Senior Notes due 2021		—			150,000
5.125% Senior Notes due 2022		—			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			390,000
5.500% Senior Notes due 2028		450,000			—
5.000% Senior Notes due 2029		475,000			—
Other long-term debt		3,625			4,821
Less: unamortized debt issuance costs, discount and premium		(30,802	)		(31,400	)
		3,122,426			3,149,099
Less: current portion		(153,478	)		(43,679	)
Long-term debt	$	2,968,948		$	3,105,420

Summary of Aggregate Maturities of Long-Term Debt

The aggregate maturities of long-term debt at December 31, 2020 were as follows (in thousands):

2021	$	153,478
2022		284,282
2023		1,400,468
2024		390,000
2025		—
Thereafter		925,000
Total	$	3,153,228

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Equity-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Activity

Stock option activity during 2018, 2019 and 2020 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2018		974,566		$	47.89		7.46	$	3,802
Options granted		374,700			37.54		9.21		246
Options exercised		(20,989	)		17.83	N/A			383
Options cancelled		(128,737	)		50.83	N/A		N/A
Options outstanding at December 31, 2018		1,199,540			44.64		7.26		2,717
Options granted		605,200			28.50		9.21		1,343
Options exercised		(55,671	)		19.05	N/A			658
Options cancelled		(389,001	)		40.84	N/A		N/A
Options outstanding at December 31, 2019		1,360,068			39.40		7.57		1,650
Options granted		507,600			33.13		9.18		157
Options exercised		(68,700	)		29.15	N/A			854
Options cancelled		(288,662	)		39.67	N/A		N/A
Options outstanding at December 31, 2020		1,510,306		$	37.56		7.35	$	1,414
Options exercisable at December 31, 2019		513,290		$	48.08		5.88	$	512
Options exercisable at December 31, 2020		596,606		$	45.37		5.55	$	543

Schedule of Stock Options Valuation Assumptions

The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2020, 2019 and 2018:

	Year Ended December 31,
	2020			2019			2018
Weighted average grant-date fair value of options	$	12.37		$	17.59		$	13.67
Risk-free interest rate		1.6	%		2.4	%		2.2	%
Expected volatility		41	%		38	%		37	%
Expected life (in years)		5.0			5.0			5.1

Restricted Stock Activity

Restricted stock activity during 2018, 2019 and 2020 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2018		809,868		$	50.19
Granted		480,137			36.84
Cancelled		(88,989	)		47.57
Vested		(395,959	)		50.41
Unvested at December 31, 2018		805,057		$	42.40
Granted		700,937			28.77
Cancelled		(389,684	)		33.50
Vested		(311,174	)		44.23
Unvested at December 31, 2019		805,136		$	34.14
Granted		637,312			25.82
Cancelled		(129,683	)		34.56
Vested		(289,769	)		35.88
Unvested at December 31, 2020		1,022,996		$	28.41

Restricted Stock Unit Activity

Restricted stock unit activity during 2018, 2019 and 2020 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2017		360,909		$	50.04
Granted		285,358			42.26
Cancelled		(89,173	)		55.44
Vested		(72,983	)		49.64
Unvested at December 31, 2018		484,111		$	44.52
Granted		234,408			34.54
Cancelled		(271,162	)		45.17
Vested		—			—
Unvested at December 31, 2019		447,357		$	38.89
Granted		583,680			10.60
Performance adjustment		117,772			13.50
Cancelled		(63,056	)		43.35
Vested		(12,691	)		42.09
Unvested at December 31, 2020		1,073,062		$	20.15

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Components of Provision for Income Taxes

Provision for income taxes consists of the following for the periods presented (in thousands):

	Year Ended December 31,
	2020			2019			2018
Current:
Federal	$	(18,215	)	$	18,954		$	13,962
State		4,981			3,440			1,113
Foreign		732			1,602			1,569
Total current		(12,502	)		23,996			16,644
Deferred:
Federal		46,442			(1,572	)		(7,176	)
State		564			2,509			(10	)
Foreign		6,102			152			449
Total deferred provision		53,108			1,089			(6,737	)
Provision for income taxes	$	40,606		$	25,085		$	9,907

Effective Income Tax Rate

A reconciliation of the U.S. federal statutory rate to the effective tax rate is as follows for the periods presented:

	Year Ended December 31,
	2020			2019			2018
U.S. federal statutory rate on income before income taxes		21.0	%		21.0	%		21.0	%
Impact of foreign operations		(0.5	)		1.1			0.6
Effects of statutory rate change		3.2			—			—
Impacts of SAB 118		—			—			(16.4	)
State income taxes, net of federal tax effect		5.1			5.8			3.4
Permanent differences		1.5			3.3			9.2
Change in valuation allowance		127.4			0.6			(0.3	)
Unrecognized tax benefit release		(0.4	)		0.5			(0.9	)
Federal tax credits		(1.0	)		(2.2	)		(2.3	)
Basis recognition related to foreign divestiture		(129.9	)		—			—
CARES Act impacts to net operating losses		(4.5	)		—			—
Other		0.2			1.9			0.4
Effective income tax rate		22.1	%		32.0	%		14.7	%

Summary of Domestic and Foreign Components of Income from Continuing Operations before Income Taxes

The domestic and foreign components of income from continuing operations before income taxes for continuing operations are as follows (in thousands):

	Year Ended December 31,
	2020		2019		2018
Foreign	$	9,904	$	6,070	$	9,947
Domestic		173,893		72,325		57,448
Income from continuing operations before income taxes	$	183,797	$	78,395	$	67,395

Deferred Tax Assets and Liabilities

	December 31,
	2020			2019
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$	7,682		$	9,913
Bad debt allowance		1,243			996
Accrued compensation and severance		20,889			14,241
Insurance reserves		18,497			16,485
Leases		846			800
Accrued expenses		11,817			1,020
Interest carryforwards		3,374			40,792
Lease right-of-use liabilities		24,402			26,375
Fixed asset basis difference		—			14,714
Basis in foreign subsidiary		239,073			—
Other assets		13,251			2,777
Total gross deferred tax assets		341,074			128,113
Less: valuation allowance		(241,225	)		(6,859	)
Deferred tax assets		99,849			121,254
Deferred tax liabilities:
Fixed asset basis difference		(5,553	)		—
Prepaid items		(2,960	)		(2,163	)
Intangible assets		(115,196	)		(100,881	)
Lease right-of-use assets		(22,948	)		(24,898	)
Other liabilities		—			(12,793	)
Total deferred tax liabilities		(146,657	)		(140,735	)
Total net deferred tax liability	$	(46,808	)	$	(19,481	)

Unrecognized Income Tax Benefits Net of Federal Benefit

A reconciliation of the beginning and ending amount of unrecognized income tax benefits, net of the federal benefit, is as follows (in thousands):

	2020			2019
Balance at January 1	$	2,441		$	713
Additions based on tax positions related to the current year		—			3,001
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities		(381	)		(1,273	)
Balance at December 31	$	2,060		$	2,441

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities

	Carrying Amount				Fair Value
	December 31,				December 31,
	2020		2019		2020		2019
Amended and Restated Senior Credit Facility	$	1,175,437	$	1,668,062	$	1,175,437	$	1,668,062
6.125% Senior Notes due 2021	$	—	$	149,254	$	—	$	149,441
5.125% Senior Notes due 2022	$	—	$	297,761	$	—	$	299,994
5.625% Senior Notes due 2023	$	646,344	$	644,771	$	647,960	$	655,249
6.500% Senior Notes due 2024	$	385,636	$	384,430	$	393,850	$	398,366
5.500% Senior Notes due 2028	$	443,139	$	—	$	475,931	$	—
5.000% Senior Notes due 2029	$	468,245	$	—	$	499,852	$	—
Other long-term debt	$	3,625	$	4,821	$	3,625	$	4,821
Derivative instruments	$	84,584	$	68,915	$	84,584	$	68,915

Noncontrolling Interests (Tables)

12 Months Ended

Dec. 31, 2020

Noncontrolling Interest [Abstract]

Summary of Redeemable Noncontrolling Interests

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at January 1, 2019	$	28,806
Acquisition of redeemable noncontrolling interests		3,300
Net income attributable to noncontrolling interests		1,199
Distributions to noncontrolling interests		(154	)
Balance at December 31, 2019		33,151
Acquisition of redeemable noncontrolling interests		20,147
Net income attributable to noncontrolling interests		2,933
Distributions to noncontrolling interests		(916	)
Balance at December 31, 2020	$	55,315

Accumulated Other Comprehensive Loss (Tables)

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Components of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments			Pension Plan			Total
Balance at January 1, 2018	$	(376,740	)	$	7,167		$	(4,545	)	$	(374,118	)
Foreign currency translation (loss) gain		(127,788	)		—			267			(127,521	)
Gain on derivative instruments, net of tax of $12.7 million		—			36,799			—			36,799
Pension liability adjustment, net of tax of $0.3 million		—			—			2,463			2,463
Balance at December 31, 2018		(504,528	)		43,966			(1,815	)		(462,377	)
Foreign currency translation gain (loss)		69,895			—			(84	)		69,811
Loss on derivative instruments, net of tax of $(3.6) million		—			(19,008	)		—			(19,008	)
Pension liability adjustment, net of tax of $(0.6) million		—			—			(3,310	)		(3,310	)
Balance at December 31, 2019		(434,633	)		24,958			(5,209	)		(414,884	)
Foreign currency translation gain (loss)		61,532			—			(285	)		61,247
Loss on derivative instruments, net of tax of $(3.9) million		—			(11,272	)		—			(11,272	)
Pension liability adjustment, net of tax of $(0.8) million		—			—			(6,456	)		(6,456	)
Balance at December 31, 2020	$	(373,101	)	$	13,686		$	(11,950	)	$	(371,365	)

Quarterly Information (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2020

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

The tables below present summarized unaudited quarterly results of operations for the years ended December 31, 2020 and 2019.

	Quarter Ended
	March 31,		June 30,		September 30,			December 31,
	(In thousands except per share amounts)
2020:
Revenue	$	509,217	$	491,475	$	547,961		$	541,276
Income from continuing operations, net of taxes	$	21,251	$	30,721	$	45,063		$	46,156
Income (loss) from discontinued operations, net of taxes	$	12,816	$	10,993	$	(7,502	)	$	(828,697	)	⁽¹⁾
Net income (loss) attributable to Acadia Healthcare Company, Inc. stockholders	$	33,463	$	41,079	$	36,998		$	(783,672	)	⁽¹⁾
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	0.24	$	0.34	$	0.51		$	0.51
Income (loss) from discontinued operations	$	0.14	$	0.13	$	(0.09	)	$	(9.42	)	⁽¹⁾
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	0.38	$	0.47	$	0.42		$	(8.91	)	⁽¹⁾
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	0.23	$	0.34	$	0.50		$	0.50
Income (loss) from discontinued operations	$	0.15	$	0.12	$	(0.08	)	$	(9.28	)	⁽¹⁾
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	0.38	$	0.46	$	0.42		$	(8.78	)	⁽¹⁾

2019:
Revenue	$	487,960	$	509,813	$	509,383		$	501,225
Income (loss) from continuing operations, net of taxes	$	13,618	$	26,964	$	24,920		$	(12,192	)	⁽²⁾
Income from discontinued operations, net of taxes	$	15,893	$	21,237	$	17,803		$	1,879		⁽²⁾
Net income (loss) attributable to Acadia Healthcare Company, Inc. stockholders	$	29,471	$	48,140	$	42,566		$	(11,254	)	⁽²⁾
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income (loss) from continuing operations attributable to Acadia Healthcare Company, Inc.	$	0.16	$	0.31	$	0.28		$	(0.15	)	⁽²⁾
Income from discontinued operations	$	0.18	$	0.24	$	0.21		$	0.02		⁽²⁾
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	0.34	$	0.55	$	0.49		$	(0.13	)	⁽²⁾
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income (loss) from continuing operations attributable to Acadia Healthcare Company, Inc.	$	0.15	$	0.31	$	0.28		$	(0.15	)	⁽²⁾
Income from discontinued operations	$	0.19	$	0.24	$	0.20		$	0.02		⁽²⁾
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	0.34	$	0.55	$	0.48		$	(0.13	)	⁽²⁾

(1)	Includes U.K. loss on sale of $867.3 million which includes approximately $356.2 million of non-cash goodwill impairment.

(2)	Includes loss on impairment of $27.2 million in continuing operations and $27.2 million in discontinued operations.

Financial Information for the Company and Its Subsidiaries (Tables)

12 Months Ended

Dec. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summarized Balance Sheet

Summarized balance sheet information (in thousands):

	December 31,
	2020		2019
Current assets	$	654,735	$	421,653
Property and equipment, net		1,421,875		1,313,830
Goodwill		1,992,305		1,992,344
Total noncurrent assets		3,640,809		3,516,967

Current liabilities		626,419		305,131
Long-term debt		2,786,125		2,877,602
Total noncurrent liabilities		3,045,981		3,159,489
Redeemable noncontrolling interests		—		—
Total equity		623,144		474,000

Summarized Statements of Income (Loss)

Summarized operating results information (in thousands):

	For the Year Ended December 31, 2020
Revenue	$	1,943,734
Income from continuing operations before income taxes		161,293
Net loss		(269,231	)
Net loss attributable to Acadia Healthcare Company, Inc.		(269,231	)

Description of Business and Basis of Presentation - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2020 USD ($) Facility Bed State	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Accounting Policies [Abstract]
Number of facilities \| Facility	572
Number of beds \| Bed	18,100
Number of operating states \| State	40
General and administrative expenses \| $	$ 97.8	$ 90.4	$ 86.6

Summary of Significant Accounting Policies - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Dec. 31, 2020 USD ($) Segment	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Significant Accounting Policies [Line Items]
Maximum professional liability aggregate policy limit		$ 75,000,000.0
Professional and general liability reserve	$ 77,500,000	77,500,000	$ 52,600,000
Professional and general liability reserve current	9,700,000	9,700,000	4,700,000
Professional and general liability reserve noncurrent	67,800,000	67,800,000	47,900,000
Insurance receivable	27,200,000	27,200,000	8,500,000
Insurance receivable - current portion	6,792,000	6,792,000	3,030,000
Insurance receivable noncurrent	20,400,000	20,400,000	5,500,000
Workers compensation insurance claims deductible per accident		500,000
Reserve for workers compensation liability		23,000,000.0	20,800,000
Accrued salaries and benefits	12,000,000.0	12,000,000.0	10,000,000.0
Other long-term liabilities	$ 11,000,000.0	11,000,000.0	10,800,000
Depreciation expense		95,300,000	87,900,000	$ 80,300,000
Impairment of long-lived assets		4,200,000	$ 27,200,000	$ 0
Non-cash impairment charge related to indefinite-lived assets		$ 600,000
Number of operating segment \| Segment	1
Number of reporting unit \| Segment	1
ASU 2017-12 [Member]
Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2019	Jan. 01, 2019
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true	true
U.S. Facilities [Member]
Significant Accounting Policies [Line Items]
Goodwill impairment loss		$ 0
Discontinued Operations [Member] \| U.K. Facilities [Member]
Significant Accounting Policies [Line Items]
Goodwill impairment loss		356,200,000
Closed Facilities [Member] \| U.S. Facilities [Member]
Significant Accounting Policies [Line Items]
Non-cash impairment charge related to indefinite-lived assets		600,000
Maximum [Member]
Significant Accounting Policies [Line Items]
Maximum self insured professional liability limit per claim		$ 3,000,000.0
Maximum [Member] \| Building and Improvements [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life		50 years
Maximum [Member] \| Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life		7 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Maximum professional liability retention limit		$ 3,000,000.0
Minimum [Member] \| Building and Improvements [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life		10 years
Minimum [Member] \| Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life		3 years

Summary of Significant Accounting Policies - Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid expenses	$ 19,480	$ 17,343
Workers’ compensation deposits – current portion	12,000	10,000
Other receivables	10,025	10,661
Insurance receivable - current portion	6,792	3,030
Cost report receivable	5,818	13,723
Inventory	4,851	4,075
Income taxes receivable	897	4,786
Other	1,469	1,349
Other current assets	$ 61,332	$ 64,967

Summary of Significant Accounting Policies - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accounts Payable And Accrued Liabilities Current [Abstract]
Accrued interest	$ 40,479	$ 33,323
Unearned income	35,946	1,895
Finance lease liabilities	32,188	3,765
Accrued expenses	28,452	18,595
Income taxes payable	16,345
Insurance liability – current portion	9,700	4,731
Accrued property taxes	6,763	4,755
Government relief funds	5,495
Other	3,085	2,170
Other accrued liabilities	$ 178,453	$ 69,234

U.K. Sale - Additional Information (Detail) - USD ($) $ in Millions			12 Months Ended
	Jan. 19, 2021	Jan. 05, 2021	Dec. 31, 2020	Dec. 31, 2019
Tranche B-4 Facilities [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayments of debt	$ 767.9	$ 105.0
Discontinued Operations [Member] \| U.K. Sales [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on sale			$ 867.3
Goodwill impairment loss			356.2
Cash paid for capital expenditures			$ 48.4	$ 59.6
Discontinued Operations [Member] \| U.K. Sales [Member] \| Subsequent Event [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross proceeds from sale of business	1,525.0
Cash retained by buyer	75.0
Transaction costs	16.0
Settlement of existing foreign currency hedging liabilities	85.0
Net proceeds from sale of business	1,425.0
Net proceeds from sale of business, after deducting cash retained by buyer	1,350.0
Cash	345.0
Discontinued Operations [Member] \| Tranche B-4 Facilities [Member] \| U.K. Sales [Member] \| Subsequent Event [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayments of debt	768.0
Term Loan A- Facility [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayments of debt	311.7
Term Loan A- Facility [Member] \| Discontinued Operations [Member] \| U.K. Sales [Member] \| Subsequent Event [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayments of debt	$ 312.0

U.K. Sale - Result of Operation (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) income from discontinued operations	$ (828,697)	$ (7,502)	$ 10,993	$ 12,816	$ 1,879	$ 17,803	$ 21,237	$ 15,893	$ (812,390)	$ 56,812	$ (232,974)
Discontinued Operations [Member] \| U.K. Sales [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue									1,119,768	1,099,081	1,107,747
Salaries, wages and benefits									632,134	609,823	610,031
Professional fees									127,291	122,532	117,376
Supplies									38,285	37,527	37,852
Rents and leases									47,748	46,743	45,967
Other operating expenses									113,534	115,897	110,827
Depreciation and amortization									74,935	76,121	78,490
Interest expense, net									(417)	(231)	876
Loss on sale									867,324
Loss on impairment									20,239	27,169	337,889
Transaction-related expenses									8,719	5,907	4,788
Total expenses									1,929,792	1,041,488	1,344,096
(Loss) income from discontinued operations before income taxes									(810,024)	57,593	(236,349)
Provision for (benefit from) income taxes									2,366	781	(3,375)
(Loss) income from discontinued operations									$ (812,390)	$ 56,812	$ (232,974)

U.K. Sale - Major Classes of Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current assets of discontinued operations	$ 1,809,815	$ 88,846
Current liabilities:
Current liabilities of discontinued operations	660,027	148,692
Discontinued Operations [Member] \| U.K. Sales [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	75,051	24,657
Accounts receivable, net	52,196	50,912
Other current assets	13,361	13,277
Current assets of discontinued operations	140,608	88,846
Property and equipment, net	1,297,923	1,724,447
Goodwill		364,027
Intangible assets, net	22,289	21,531
Operating lease right-of-use assets	341,289	404,042
Other assets	7,706	13,127
Total assets of discontinued operations	1,809,815	2,616,020
Current liabilities:
Accounts payable	44,929	36,788
Current portion of operating lease liabilities	11,141	11,021
Other current liabilities	136,895	100,883
Current liabilities of discontinued operations	192,965	148,692
Operating lease liabilities	387,607	416,609
Deferred tax liabilities	57,230	49,040
Other liabilities	22,225	21,435
Total liabilities of discontinued operations	$ 660,027	$ 635,776

U.K. Sale - Summary of Funded Status (Unfunded Liability) (Detail) - Discontinued Operations [Member] - U.K. Sales [Member] - Pension Plan [Member] - Partnership in Care Benefits Plan [Member] - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Projected benefit obligation	$ 80,158	$ 66,468
Fair value of plan assets	71,979	62,207
Unfunded liability	$ 8,179	$ 4,261

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References + Details

The CARES Act - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 24, 2020	Aug. 31, 2020	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
CARES Act [Line Items]
Received benefit in form of refunds and lower future tax payments					$ 51,600	$ 51,600
Received benefit related to interest expense					22,800	22,800
Received benefit related to qualified improvement property legislation					20,500	20,500
Expected permanent cash benefit due to loss					$ 8,300	$ 8,300
Effective income tax rate reconciliation at federal statutory income tax rate					21.00%	21.00%	21.00%	35.00%
Other income					$ 32,819
CARES Act [Member]
CARES Act [Line Items]
Offer of eligible relief amount				$ 100,000,000
Additional offer of eligible relief amount	$ 75,000,000
Cash benefit relating to delay of payment of social security payroll taxes					$ 39,000
Net operating loss carryforwards and carrybacks offset percentage of taxable income					100.00%
Net operating loss carried back period					5 years
CARES Act [Member] \| Medicare [Member]
CARES Act [Line Items]
Percentage of increase in medicare reimbursement rate				2.00%
CARES Act [Member] \| Public Health and Social Services Emergency Fund [Member]
CARES Act [Line Items]
Receipt of CARES Act of 2020 aid amount				$ 19,700	$ 34,900
Receipt of additional CARES Act of 2020 aid amount		$ 12,800
Other income			$ 32,800
CARES Act [Member] \| CMS’ Accelerated and Advance Payment Program [Member] \| Medicare [Member]
CARES Act [Line Items]
Amount of advance payment received				$ 45,000

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Accounts receivable, net		$ 15,340	$ (18,714)	$ (19,702)
Cost report receivables		5,818	13,723
Net adjustments to estimated cost report settlements resulted in (decreases) increases to revenue		(1,300)	(400)	500
Costs of providing charity care services		4,400	4,300	$ 4,700
CARES Act [Member] \| CMS’ Accelerated and Advance Payment Program [Member] \| Medicare [Member]
Disaggregation of Revenue [Line Items]
Amount of advance payment received	$ 45,000
Repayment of advanced payments description	In April 2020, the Company received approximately $45 million from CMS’ Accelerated and Advance Payment Program for Medicare providers, which the Company expects to repay over the 12 month period beginning in April 2021. Once repayment begins, the amount will be recouped from the provider’s or supplier’s new Medicare claims.
Expected repayment period	12 months
Repayment of advanced payments period	2021-04
CARES Act [Member] \| CMS’ Accelerated and Advance Payment Program [Member] \| Medicare [Member] \| Other Accrued Liabilities [Member]
Disaggregation of Revenue [Line Items]
Contract liabilities		35,900
CARES Act [Member] \| CMS’ Accelerated and Advance Payment Program [Member] \| Medicare [Member] \| Other Liabilities [Member]
Disaggregation of Revenue [Line Items]
Contract liabilities		11,300
Accounting Standards Update 2014-09
Disaggregation of Revenue [Line Items]
Accounts receivable, net		$ 62,100	$ 45,900

Revenue - Schedule of U.S. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Revenue	$ 541,276	$ 547,961	$ 491,475	$ 509,217	$ 501,225	$ 509,383	$ 509,813	$ 487,960	$ 2,089,929	$ 2,008,381	$ 1,904,695
U.S. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue									2,089,929	2,008,381	1,904,695
U.S. Facilities [Member] \| Acute Inpatient Psychiatric Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue									984,609	912,097	814,124
U.S. Facilities [Member] \| Specialty Treatment Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue									802,022	788,232	761,017
U.S. Facilities [Member] \| Residential Treatment Centers [Member]
Disaggregation of Revenue [Line Items]
Revenue									281,158	286,959	293,053
U.S. Facilities [Member] \| Outpatient Community-Based Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue									$ 22,140	$ 21,093	$ 36,501

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenue - Schedule of Revenue and Percentage Generated by Each Payor Type in U.S Facilities (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 541,276	$ 547,961	$ 491,475	$ 509,217	$ 501,225	$ 509,383	$ 509,813	$ 487,960	$ 2,089,929	$ 2,008,381	$ 1,904,695
U.S. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue									$ 2,089,929	$ 2,008,381	$ 1,904,695
Revenue, Percentage									100.00%	100.00%	100.00%
U.S. Facilities [Member] \| Commercial [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue									$ 596,698	$ 565,350	$ 573,089
Revenue, Percentage									28.50%	28.20%	30.10%
U.S. Facilities [Member] \| Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue									$ 330,070	$ 294,691	$ 280,340
Revenue, Percentage									15.80%	14.70%	14.70%
U.S. Facilities [Member] \| Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue									$ 1,037,852	$ 1,007,102	$ 893,644
Revenue, Percentage									49.70%	50.10%	46.90%
U.S. Facilities [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue									$ 98,302	$ 118,716	$ 134,054
Revenue, Percentage									4.70%	5.90%	7.10%
U.S. Facilities [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue									$ 27,007	$ 22,522	$ 23,568
Revenue, Percentage									1.30%	1.10%	1.20%

- Definition

+ References

+ Details

Revenue - Summary of the Activity in Unearned Revenue in U.S. Facilities (Detail) - U.S. Facilities [Member] - Unearned Revenue [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Disaggregation of Revenue [Line Items]
Beginning Balance	$ 1,895
Payments received	51,044
Revenue recognized	(5,743)
Ending Balance	$ 47,196

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Numerator:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.									$ 140,258	$ 52,111	$ 57,224
(Loss) income from discontinued operations									(812,390)	56,812	(232,974)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$ (783,672)	$ 36,998	$ 41,079	$ 33,463	$ (11,254)	$ 42,566	$ 48,140	$ 29,471	$ (672,132)	$ 108,923	$ (175,750)
Denominator:
Weighted average shares outstanding for basic earnings per share									87,875	87,612	87,288
Effects of dilutive instruments									720	204	127
Shares used in computing diluted earnings per common share									88,595	87,816	87,415
Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$ 0.51	$ 0.51	$ 0.34	$ 0.24	$ (0.15)	$ 0.28	$ 0.31	$ 0.16	$ 1.60	$ 0.59	$ 0.66
(Loss) income from discontinued operations	(9.42)	(0.09)	0.13	0.14	0.02	0.21	0.24	0.18	(9.25)	0.65	(2.67)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	(8.91)	0.42	0.47	0.38	(0.13)	0.49	0.55	0.34	(7.65)	1.24	(2.01)
Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	0.50	0.50	0.34	0.23	(0.15)	0.28	0.31	0.15	1.58	0.59	0.65
(Loss) income from discontinued operations	(9.28)	(0.08)	0.12	0.15	0.02	0.20	0.24	0.19	(9.17)	0.65	(2.66)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$ (8.78)	$ 0.42	$ 0.46	$ 0.38	$ (0.13)	$ 0.48	$ 0.55	$ 0.34	$ (7.59)	$ 1.24	$ (2.01)

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	1.9	2.2	1.9

Acquisitions - Additional Information (Detail) $ in Millions	Apr. 01, 2019 USD ($) Bed	Feb. 15, 2019 USD ($) Bed Center	Dec. 31, 2020 Bed
Business Acquisition [Line Items]
Number of beds \| Bed			18,100
Bradford Recovery Center [Member]
Business Acquisition [Line Items]
Number of beds \| Bed	46
Business acquisition cash consideration \| $	$ 4.5
Whittier Pavilion [Member] \| Massachusetts [Member]
Business Acquisition [Line Items]
Number of beds \| Bed		71
Business acquisition cash consideration \| $		$ 17.9
Mission Treatment [Member] \| California, Nevada, Arizona and Oklahoma [Member]
Business Acquisition [Line Items]
Business acquisition cash consideration \| $		$ 22.5
Number of comprehensive treatment centers operates \| Center		9

Acquisitions - Summary of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Business Combinations [Abstract]
Goodwill balance	$ 2,085,104	$ 2,044,837
Increase from contribution of redeemable noncontrolling interests	20,200	3,300
Increase from 2019 acquisitions		36,967
Adjustments related to 2019 acquisitions	(40)
Goodwill balance	$ 2,105,264	$ 2,085,104

Acquisitions - Transaction Related Expenses as Incurred (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Combinations [Abstract]
Legal, accounting and other acquisition-related costs	$ 8,252	$ 3,030	$ 3,152
Termination, restructuring and strategic review costs	3,468	12,598	12,534
Management transition costs		5,529	14,033
Transaction-related expenses	$ 11,720	$ 21,157	$ 29,719

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,072,539	$ 1,860,666
Less: accumulated depreciation	(449,643)	(361,079)
Property and equipment, net	1,622,896	1,499,587
Land [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	144,221	138,325
Building and Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,490,149	1,275,610
Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	220,690	199,264
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 217,479	$ 247,467

Property and Equipment - Additional information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Loss on impairment	$ 4.2	$ 27.2
Other Assets [Member]
Property Plant And Equipment [Line Items]
Assets held for sale	$ 17.1	$ 18.9

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	$ 1,131	$ 3,231
Intangible assets not subject to amortization, Gross Carrying Amount	68,535	68,826
Total	69,666	72,057
Intangible assets subject to amortization, Accumulated Amortization	(1,131)	(3,231)
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Total	(1,131)	(3,231)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	11,873	12,020
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	39,526	39,735
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	17,136	17,071
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Contract Intangible Assets [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	0	2,100
Intangible assets subject to amortization, Accumulated Amortization	0	(2,100)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,131	1,131
Intangible assets subject to amortization, Accumulated Amortization	$ (1,131)	$ (1,131)

Other Intangible Assets - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2020 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Non-cash impairment charge related to indefinite-lived assets	$ 0.6

Leases - Additional Information (Detail)	12 Months Ended
Leases - Additional Information (Detail)	Dec. 31, 2020
Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	5 years
Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	30 years
Copiers and Equipment [Member] \| Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	1 year
Copiers and Equipment [Member] \| Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	3 years

Leases - Schedule of Leases on Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	$ 96,937	$ 97,795
Total	131,558	133,284
Finance lease liabilities	32,188	3,765
Operating lease liabilities	18,916	18,119
Finance lease liabilities	10,744
Operating lease liabilities	84,029	85,643
Total	145,877	147,246
Property and Equipment, Net [Member]
Lessee Lease Description [Line Items]
Finance lease right-of-use assets	34,621	35,489
Operating Lease Right-of-use Assets [Member]
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	96,937	97,795
Other Accrued Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	32,188	3,765
Current Portion of Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	18,916	18,119
Other Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	10,744	39,719
Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	$ 84,029	$ 85,643

Leases - Schedule of Weighted-average Remaining Lease Terms and Discount Rates (Detail)	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Finance lease, weighted average remaining lease term (years)	6 years 8 months 12 days	6 years 6 months
Operating lease, weighted average remaining term (years)	8 years 6 months	8 years 7 months 6 days
Finance lease, weighted average discount rate percent	5.90%	5.30%
Operating lease, weighted average discount rate percent	6.50%	6.50%

Leases - Schedule of Lease Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Finance lease costs:
Depreciation of leased assets	$ 868	$ 907
Interest of lease liabilities	3,214	3,226
Total finance lease costs	4,082	4,133
Operating lease costs	27,050	25,630
Variable lease costs	2,501	1,966
Short term lease costs	3,558	4,790
Other lease costs	4,253	3,101
Total rents and leases	37,362	35,487
Total lease costs	$ 41,444	$ 39,620

Leases - Schedule of Undiscounted Cash Flows for Finance and Operating Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Finance Leases
2021	$ 32,909
2022	990
2023	990
2024	1,007
2025	1,089
Thereafter	23,999
Total minimum lease payments	60,984
Less: amount of lease payments representing interest	18,052
Present value of future minimum lease payments	42,932
Less: Current portion of lease liabilities	32,188	$ 3,765
Noncurrent lease liabilities	10,744
Operating Leases
2021	25,015
2022	21,032
2023	17,336
2024	14,832
2025	12,101
Thereafter	52,866
Total minimum lease payments	143,182
Less: amount of lease payments representing interest	40,237
Present value of future minimum lease payments	102,945
Current portion of operating lease liabilities	18,916	18,119
Operating lease liabilities	$ 84,029	$ 85,643

Leases - Schedule of Supplemental Data (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 26,810	$ 25,086
Operating cash flows for finance leases	3,214	3,226
Financing cash flows for finance leases	551	862
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 21,285	$ 21,809

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Sep. 21, 2015
Debt Instrument [Line Items]
Other long-term debt	$ 3,625	$ 4,821
Less: unamortized debt issuance costs, discount and premium	(30,802)	(31,400)
Long-term debt	3,122,426	3,149,099
Less: current portion	(153,478)	(43,679)
Long-term debt	2,968,948	3,105,420
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term A Loan [Member]
Debt Instrument [Line Items]
Senior Secured	311,733	346,750
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Senior Secured	872,870	1,338,928
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Senior Notes		150,000
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Senior Notes		300,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes	650,000	650,000	$ 650,000
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Senior Notes	390,000	$ 390,000
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Senior Notes	450,000
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Senior Notes	$ 475,000

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Oct. 14, 2020	Jun. 24, 2020	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%							6.125%
Senior notes maturity year	2021	2021
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%						5.125%
Senior notes maturity year	2022	2022
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%				5.625%	5.625%
Senior notes maturity year	2023	2023
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%			6.50%
Senior notes maturity year	2024	2024
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.50%	5.50%		5.50%
Senior notes maturity year	2028	2028
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.00%	5.00%	5.00%
Senior notes maturity year	2029	2029

Long-Term Debt (Amended and Restated Senior Credit Facility) - Additional Information (Detail) - USD ($) $ in Thousands															3 Months Ended				12 Months Ended
	Jan. 19, 2021	Jan. 05, 2021	Nov. 13, 2020	Apr. 21, 2020	Nov. 15, 2019	Feb. 27, 2019	Feb. 06, 2019	Apr. 17, 2018	Mar. 29, 2018	Mar. 22, 2018	Mar. 21, 2018	Dec. 15, 2015	Dec. 31, 2012	Apr. 01, 2011	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2020	Dec. 31, 2018	Dec. 15, 2014
Debt Instrument [Line Items]
Debt extinguishment costs																			$ (7,233)	$ (1,815)
Term loan repayments					$ 20,000			$ 15,000
Consolidated funded debt, unrestricted and unencumbered cash to consolidated EBITDA																					$ 50,000
Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit									$ 400,000
Line of credit outstanding principal amount			$ 352,400
Repayments of credit facility	$ 311,700
Tranche B-4 Facilities [Member]
Debt Instrument [Line Items]
Repayments of credit facility	$ 767,900	$ 105,000
Term loan repayments					13,000			9,900
Tranche B-3 Facility [Member]
Debt Instrument [Line Items]
Term loan repayments					$ 7,000			$ 5,100
Eurodollar [Member]
Debt Instrument [Line Items]
Interest on borrowings																			2.50%
Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest on borrowings																			1.50%
Amended and Restated Senior Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into an agreement													Dec. 31, 2012	Apr. 01, 2011
Debt instrument maturity date												Nov. 30, 2021							Nov. 30, 2022
Amount available under revolving line of credit																			$ 441,600
Amended and Restated Senior Credit Facility [Member] \| March 31, 2021 to September 30, 2022 [Member]
Debt Instrument [Line Items]
Term loan principal repayments																			9,500
Amended and Restated Senior Credit Facility [Member] \| Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount																			$ 17,400
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member]
Debt Instrument [Line Items]
Term loan repayments																		$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| March 31, 2019 to December 31, 2019 [Member]
Debt Instrument [Line Items]
Term loan repayments																	$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| September 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan repayments																$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| March 31, 2020 to December 31, 2020 [Member]
Debt Instrument [Line Items]
Term loan repayments															$ 2,300
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Revolving credit facility applicable rate									0.25%
Debt extinguishment costs			$ 1,000							$ 900
Debt instrument maturity date			Nov. 30, 2022
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member] \| Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit			$ 459,000						$ 500,000
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member] \| Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit									$ 380,000
Line of credit outstanding principal amount			$ 318,900
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member]
Debt Instrument [Line Items]
Basis spread on variable rate																			1.00%
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Interest on borrowings										2.50%	2.75%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member]
Debt Instrument [Line Items]
Basis spread on variable rate																			0.50%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Interest on borrowings										1.50%	1.75%
Amended and Restated Senior Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Interest on borrowings																			2.50%
Eleventh Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement							Feb. 06, 2019
Twelfth Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement						Feb. 27, 2019
Thirteenth Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement				Apr. 21, 2020

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($)		12 Months Ended
	Mar. 12, 2013	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issued Senior Notes	$ 150,000,000.0
Debt instrument interest rate	6.125%	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		payable semi-annually in arrears on March 15 and September 15 of each year.

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes Due 2022 [Member] - USD ($)		12 Months Ended
	Jul. 01, 2014	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issued Senior Notes	$ 300,000,000.0
Debt instrument interest rate	5.125%	5.125%	5.125%
Debt instrument maturity date	Jul. 01, 2022
Interest on the notes		payable semi-annually in arrears on January 1 and July 1 of each year.

Long-Term Debt (Redemption of 6.125% Senior Notes and 5.125% Senior Notes) - Additional Information (Detail) - USD ($) $ in Millions		12 Months Ended
	Jun. 10, 2020	Dec. 31, 2020	Dec. 31, 2019	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		6.125%	6.125%		6.125%
Debt instrument, redemption date		Jul. 10, 2020
Debt instrument, redemption price percentage of principal amount	100.00%
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		5.125%	5.125%	5.125%
Debt instrument, redemption price percentage of principal amount	100.00%
6.125% Senior Notes Due 2021 and 5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt extinguishment charge	$ 3.3

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Sep. 21, 2015	Feb. 11, 2015
Debt Instrument [Line Items]
Issued Senior Notes			$ 275,000,000.0	$ 375,000,000.0
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Senior Notes	$ 650,000,000	$ 650,000,000	$ 650,000,000.0
Debt instrument maturity date	Feb. 15, 2023
Interest on the notes	payable semi-annually in arrears on February 15 and August 15 of each year.

Long-Term Debt (6.500% Senior Notes due 2024) - Additional Information (Detail) - 6.500% Senior Notes Due 2024 [Member] - USD ($)		12 Months Ended
	Feb. 16, 2016	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issued Senior Notes	$ 390,000,000.0
Debt instrument interest rate	6.50%	6.50%	6.50%
Debt instrument maturity date	Mar. 01, 2024
Interest on the notes		payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

Long-Term Debt (Redemption of 5.265% Senior Notes and 6.500% Senior Notes) - Additional Information (Detail) - Subsequent Event [Member]	Jan. 29, 2021 USD ($)
Redemption of 5.265% Senior Notes [Member]
Debt Instrument [Line Items]
Senior Notes	$ 650,000,000
Debt instrument interest rate	5.265%
Redemption of 6.500% Senior Notes [Member]
Debt Instrument [Line Items]
Senior Notes	$ 390,000,000
Debt instrument interest rate	6.50%
Redemption of 5.265% Senior Notes and 6.500% Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, redemption date	Jan. 29, 2021
Senior Notes	$ 1,040,000,000
Payment of breakage costs	6,000,000
Estimated transaction costs	9,000,000
Debt instrument funded from cash	430,000,000
Proceeds from new senior secured credit facility	$ 625,000,000
Debt instrument term	5 years

Long-Term Debt (5.500% Senior Notes due 2028) - Additional Information (Detail) - 5.500% Senior Notes due 2028 [Member] - USD ($)	Jun. 24, 2020	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issued Senior Notes	$ 450,000,000.0
Debt instrument interest rate	5.50%	5.50%	5.50%
Debt instrument maturity date	Jul. 01, 2028
Interest on the notes	payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021

Long-Term Debt (5.000% Senior Notes due 2029) - Additional Information (Detail) - USD ($)		12 Months Ended
	Oct. 14, 2020	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2019
Debt Instrument [Line Items]
Debt extinguishment costs		$ (7,233,000)	$ (1,815,000)
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Issued Senior Notes	$ 475,000,000.0
Debt instrument interest rate	5.00%	5.00%		5.00%
Debt instrument maturity date	Apr. 15, 2029
Interest on the notes		payable semi-annually in arrears on April 15 and October 15 of each year, commencing on April 15, 2021.
Debt extinguishment charge	$ 453,300,000
Debt extinguishment costs	$ 2,900,000

Long-Term Debt (9.0% and 9.5% Revenue Bonds) - Additional Information (Detail) - USD ($) $ in Thousands		12 Months Ended
	Dec. 01, 2018	Dec. 31, 2020	Dec. 31, 2018	Nov. 11, 2012
Debt Instrument [Line Items]
Debt extinguishment charge		$ (7,233)	$ (1,815)
9.0% and 9.5% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds				$ 23,000
9.0% and 9.5% Revenue Bonds [Member] \| Fair Value [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds				25,600
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.00%
Debt instrument, redemption price percentage of principal amount	104.00%
Debt instrument, redemption date	Dec. 01, 2018
Debt extinguishment charge	$ (900)
9.0% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds				$ 7,500
Debt instrument interest rate				9.00%
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.50%
Debt instrument, redemption price percentage of principal amount	104.00%
Debt instrument, redemption date	Dec. 01, 2018
Debt extinguishment charge	$ (900)
9.5% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds				$ 15,500
Debt instrument interest rate				9.50%

Long-Term Debt (Debt Issuance Costs) - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Debt issuance costs	$ 29.8	$ 29.0
Accumulated amortization	56.0	46.2
Amortization expenses reported as interest expense	$ 9.8	$ 9.7	$ 9.0

Long-Term Debt (Other) - Summary of Aggregate Maturities of Long-Term Debt (Detail) $ in Thousands	Dec. 31, 2020 USD ($)
Debt Disclosure [Abstract]
2021	$ 153,478
2022	284,282
2023	1,400,468
2024	390,000
Thereafter	925,000
Total	$ 3,153,228

Equity - Additional Information (Detail) - shares	12 Months Ended
Equity - Additional Information (Detail) - shares	Dec. 31, 2020	Dec. 31, 2019
Equity [Line Items]
Preferred stock, number of shares proposed to be issued	10,000,000	10,000,000
Common stock, number of shares proposed to be issued	180,000,000	180,000,000
Common stock voting rights	one vote for each share
Maximum [Member]
Equity [Line Items]
Preferred stock, number of shares proposed to be issued	10,000,000
Common stock, number of shares proposed to be issued	180,000,000

Equity-Based Compensation - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	8,200,000
Equity incentive plan available for future grant	974,746
Annual increments in employee grants	25.00%
Stock options, contractual term	10 years
Equity-based compensation expense	$ 22,504,000	$ 17,307,000	$ 22,001,000
Vesting targets	500,000	(6,400,000)	(5,500,000)
Unrecognized compensation expense related to unvested options	$ 36,900,000
Vesting period	1 year 2 months 12 days
Warrant outstanding	$ 0
Deferred income tax benefit	53,108,000	1,089,000	(6,737,000)
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 5,500,000	$ 4,000,000.0	$ 6,600,000
Restricted Stock Award [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Award [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Restricted Stock Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years
Number of shares issuable at the end of the vesting period, percentage	0.00%
Restricted Stock Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Number of shares issuable at the end of the vesting period, percentage	200.00%

Equity-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, Beginning balance	1,360,068	1,199,540	974,566
Options granted	507,600	605,200	374,700
Options exercised	(68,700)	(55,671)	(20,989)
Options cancelled	(288,662)	(389,001)	(128,737)
Options outstanding, Ending balance	1,510,306	1,360,068	1,199,540	974,566
Options exercisable, Ending balance	596,606	513,290
Options outstanding, Weighted Average Exercise Price, Beginning balance	$ 39.40	$ 44.64	$ 47.89
Options granted, Weighted Average Exercise Price	33.13	28.50	37.54
Options exercised, Weighted Average Exercise Price	29.15	19.05	17.83
Options cancelled, Weighted Average Exercise Price	39.67	40.84	50.83
Options outstanding, Weighted Average Exercise Price, Ending balance	37.56	39.40	$ 44.64	$ 47.89
Options exercisable, Weighted Average Exercise Price, Ending balance	$ 45.37	$ 48.08
Options outstanding, Weighted Average Remaining Contractual Term	7 years 4 months 6 days	7 years 6 months 25 days	7 years 3 months 3 days	7 years 5 months 15 days
Options granted, Weighted Average Remaining Contractual Term	9 years 2 months 4 days	9 years 2 months 15 days	9 years 2 months 15 days
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	5 years 6 months 18 days	5 years 10 months 17 days
Options outstanding, Aggregate Intrinsic Value	$ 1,414	$ 1,650	$ 2,717	$ 3,802
Options granted, Aggregate Intrinsic Value	157	1,343	246
Options exercised, Aggregate Intrinsic Value	854	658	383
Options cancelled, Aggregate Intrinsic Value	0	0	$ 0
Options exercisable, Aggregate Intrinsic Value, Ending balance	$ 543	$ 512

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options	$ 12.37	$ 17.59	$ 13.67
Risk-free interest rate	1.60%	2.40%	2.20%
Expected volatility	41.00%	38.00%	37.00%
Expected life (in years)	5 years	5 years	5 years 1 month 6 days

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	805,136	805,057	809,868
Granted, Number of Shares	637,312	700,937	480,137
Cancelled, Number of Shares	(129,683)	(389,684)	(88,989)
Vested, Number of Shares	(289,769)	(311,174)	(395,959)
Unvested, Number of Shares/Units, Ending balance	1,022,996	805,136	805,057
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 34.14	$ 42.40	$ 50.19
Granted, Weighted Average Grant-Date Fair Value	25.82	28.77	36.84
Cancelled, Weighted Average Grant-Date Fair Value	34.56	33.50	47.57
Vested, Weighted Average Grant-Date Fair Value	35.88	44.23	50.41
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 28.41	$ 34.14	$ 42.40

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	447,357	484,111	360,909
Granted, Number of Units	583,680	234,408	285,358
Performance adjustment, Number of Units	117,772
Cancelled, Number of Units	(63,056)	(271,162)	(89,173)
Vested, Number of Units	(12,691)		(72,983)
Unvested, Number of Shares/Units, Ending balance	1,073,062	447,357	484,111
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 38.89	$ 44.52	$ 50.04
Granted, Weighted Average Grant-Date Fair Value	10.60	34.54	42.26
Performance adjustment, Weighted Average Grant-Date Fair Value	13.50
Cancelled, Weighted Average Grant-Date Fair Value	43.35	45.17	55.44
Vested, Weighted Average Grant-Date Fair Value	42.09		49.64
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 20.15	$ 38.89	$ 44.52

Income Taxes - Components of Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current:
Federal	$ (18,215)	$ 18,954	$ 13,962
State	4,981	3,440	1,113
Foreign	732	1,602	1,569
Total current	(12,502)	23,996	16,644
Deferred:
Federal	46,442	(1,572)	(7,176)
State	564	2,509	(10)
Foreign	6,102	152	449
Total deferred provision	53,108	1,089	(6,737)
Provision for income taxes	$ 40,606	$ 25,085	$ 9,907

Income Taxes - Effective Income Tax Rate (Detail)	12 Months Ended
Income Taxes - Effective Income Tax Rate (Detail)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
U.S. federal statutory rate on income before income taxes	21.00%	21.00%	21.00%	35.00%
Impact of foreign operations	(0.50%)	1.10%	0.60%
Effects of statutory rate change	3.20%
Impacts of SAB 118			(16.4)
State income taxes, net of federal tax effect	5.10%	5.80%	3.40%
Permanent differences	1.50%	3.30%	9.20%
Change in valuation allowance	127.40%	0.60%	(0.30%)
Unrecognized tax benefit release	(0.40%)	0.50%	(0.90%)
Federal tax credits	(1.00%)	(2.20%)	(2.30%)
Basis recognition related to foreign divestiture	(129.90%)
CARES Act impacts to net operating losses	(4.50%)
Other	0.20%	1.90%	0.40%
Effective income tax rate	22.10%	32.00%	14.70%

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Examination [Line Items]
Provision for income taxes	$ 40,606,000	$ 25,085,000	$ 9,907,000
Effective tax rates	22.10%	32.00%	14.70%
Effective income tax rate reconciliation at federal statutory income tax rate	21.00%	21.00%	21.00%	35.00%
Basis in foreign subsidiary	$ 239,073,000
Deferred tax assets valuation allowance	$ 239,100,000
Exemption of tax credit	1.00%	2.20%	2.30%
Valuation allowance against deferred tax assets	$ 241,225,000	$ 6,859,000
Federal net operating loss carryforwards	0	0
Foreign net operating loss carryforwards	100,000	100,000
State net operating loss carry forwards	$ 170,000,000.0	220,800,000
Operating loss carryforwards expiration start year	2022
Operating loss carryforwards expiration end year	2035
Expiration of State tax credits	2030
State tax credits	$ 600,000
Income taxes receivable	897,000	4,786,000
Income tax payable included in other accrued liabilities	16,345,000
Unrecognized tax benefits	2,060,000	2,441,000	$ 713,000
Cumulative amounts of interest and penalties recognized	500,000	600,000
Unrecognized tax benefits would impact effective tax rate	$ 400,000
Foreign dividends			$ 10,900
Earliest Tax Year [Member] \| Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service	2017
Latest Tax Year [Member] \| Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service	2019
Other Liabilities [Member]
Income Tax Examination [Line Items]
Unrecognized tax benefits	$ 2,500,000	$ 3,100,000
Foreign Tax Authority [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service minimum	2016
Period of examination by internal revenue service maximum	2019
State and Local Jurisdiction [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service minimum	2014
Period of examination by internal revenue service maximum	2019
Maximum [Member]
Income Tax Examination [Line Items]
Exemption of tax credit	50.00%
Maximum [Member] \| Payroll [Member]
Income Tax Examination [Line Items]
Exemption of tax credit	15.00%

Income Taxes - Summary of Domestic and Foreign Components of Income from Continuing Operations before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Taxes [Line Items]
Income from continuing operations before income taxes	$ 183,797	$ 78,395	$ 67,395
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Income from continuing operations before income taxes	9,904	6,070	9,947
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Income from continuing operations before income taxes	$ 173,893	$ 72,325	$ 57,448

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$ 7,682	$ 9,913
Bad debt allowance	1,243	996
Accrued compensation and severance	20,889	14,241
Insurance reserves	18,497	16,485
Leases	846	800
Accrued expenses	11,817	1,020
Interest carryforwards	3,374	40,792
Lease right-of-use liabilities	24,402	26,375
Fixed asset basis difference		14,714
Basis in foreign subsidiary	239,073
Other assets	13,251	2,777
Total gross deferred tax assets	341,074	128,113
Less: valuation allowance	(241,225)	(6,859)
Deferred tax assets	99,849	121,254
Deferred tax liabilities:
Fixed asset basis difference	(5,553)
Prepaid items	(2,960)	(2,163)
Intangible assets	(115,196)	(100,881)
Lease right-of-use assets	(22,948)	(24,898)
Other liabilities		(12,793)
Total deferred tax liabilities	(146,657)	(140,735)
Total net deferred tax liability	$ (46,808)	$ (19,481)

Income Taxes - Unrecognized Income Tax Benefits Net of Federal Benefit (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Balance at January 1	$ 2,441	$ 713
Additions based on tax positions related to the current year		3,001
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities	(381)	(1,273)
Balance at December 31	$ 2,060	$ 2,441

Derivatives - Additional Information (Detail)	1 Months Ended
Derivatives - Additional Information (Detail)	Aug. 31, 2019 USD ($)	Aug. 31, 2019 GBP (£)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Aug. 31, 2019 GBP (£)	May 31, 2016 USD ($)	May 31, 2016 GBP (£)
Derivative [Line Items]
Cross currency swap liabilities			$ 84,600,000	$ 68,900,000
Cross Currency Swap Assets [Member]
Derivative [Line Items]
Notional amount	$ 650,000,000.0				£ 538,100,000	$ 650,000,000.0	£ 449,300,000
Terminated cross currency swap derivatives	105,000,000.0
Cross currency swap agreement cash flow due to interest payment	$ 35,800,000	£ 25,400,000

Fair Value Measurements - Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	$ 3,625	$ 4,821
Carrying Amount [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	3,625	4,821
Derivative instruments	84,584	68,915
Carrying Amount [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Secured	1,175,437	1,668,062
Carrying Amount [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		149,254
Carrying Amount [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		297,761
Carrying Amount [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	646,344	644,771
Carrying Amount [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	385,636	384,430
Carrying Amount [Member] \| 5.500% Senior Notes due 2028 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	443,139
Carrying Amount [Member] \| 5.000% Senior Notes due 2029 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	468,245
Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	3,625	4,821
Derivative instruments	84,584	68,915
Fair Value [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,175,437	1,668,062
Fair Value [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		149,441
Fair Value [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		299,994
Fair Value [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	647,960	655,249
Fair Value [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	393,850	$ 398,366
Fair Value [Member] \| 5.500% Senior Notes due 2028 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	475,931
Fair Value [Member] \| 5.000% Senior Notes due 2029 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	$ 499,852

Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2020	Oct. 14, 2020	Jun. 24, 2020	Dec. 31, 2019	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%			6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%			5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%			5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%			6.50%	6.50%
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.50%		5.50%	5.50%
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.00%	5.00%		5.00%

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Transaction-related expenses	$ 4,000	$ 22,076

Noncontrolling Interests - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2020 Facility
Noncontrolling Interest [Line Items]
Number of facilities operated by non-wholly owned subsidiaries	6
Non-Wholly Owned Subsidiaries [Member] \| Minimum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	60.00%
Non-Wholly Owned Subsidiaries [Member] \| Maximum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	86.00%

Noncontrolling Interests - Summary of Redeemable Noncontrolling Interests (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Noncontrolling Interest [Abstract]
Beginning Balance	$ 33,151	$ 28,806
Acquisition of redeemable noncontrolling interests	20,147	3,300
Net income attributable to noncontrolling interests	2,933	1,199
Distributions to noncontrolling interests	(916)	(154)
Ending Balance	$ 55,315	$ 33,151

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Contribution Plan [Member] \| 401(k) [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined contribution expense	$ 3.8	$ 4.1	$ 3.5

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 2,505,381	$ 2,333,307	$ 2,572,871
Foreign currency translation (loss) gain	61,247	69,811	(127,521)
(Loss) gain on derivative instruments, net of tax of $(3.9) million, $(3.6) million and $12.7 million, respectively	(11,272)	(19,008)	36,799
Pension liability adjustment, net of tax of $(0.8) million, $(0.6) million and $0.3 million, respectively	(6,456)	(3,310)	2,463
Balance	1,899,456	2,505,381	2,333,307
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(434,633)	(504,528)	(376,740)
Foreign currency translation (loss) gain	61,532	69,895	(127,788)
Balance	(373,101)	(434,633)	(504,528)
Change in Fair Value of Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	24,958	43,966	7,167
(Loss) gain on derivative instruments, net of tax of $(3.9) million, $(3.6) million and $12.7 million, respectively	(11,272)	(19,008)	36,799
Balance	13,686	24,958	43,966
Pension Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(5,209)	(1,815)	(4,545)
Foreign currency translation (loss) gain	(285)	(84)	267
Pension liability adjustment, net of tax of $(0.8) million, $(0.6) million and $0.3 million, respectively	(6,456)	(3,310)	2,463
Balance	(11,950)	(5,209)	(1,815)
Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(414,884)	(462,377)	(374,118)
Balance	$ (371,365)	$ (414,884)	$ (462,377)

- Definition

+ References + Details

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Gain (Loss) on derivative instruments, tax	$ (3.9)	$ (3.6)	$ 12.7
Pension liability adjustment, tax	$ (0.8)	$ (0.6)	$ 0.3

Quarterly Information (Unaudited) - Schedule of Quarterly Financial Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Revenue	$ 541,276	$ 547,961	$ 491,475	$ 509,217	$ 501,225	$ 509,383	$ 509,813	$ 487,960	$ 2,089,929	$ 2,008,381	$ 1,904,695
Income from continuing operations, net of taxes	46,156	45,063	30,721	21,251	(12,192)	24,920	26,964	13,618	143,191	53,310	57,488
Income (loss) from discontinued operations, net of taxes	(828,697)	(7,502)	10,993	12,816	1,879	17,803	21,237	15,893	(812,390)	56,812	(232,974)
Net income (loss) attributable to Acadia Healthcare Company, Inc. stockholders	$ (783,672)	$ 36,998	$ 41,079	$ 33,463	$ (11,254)	$ 42,566	$ 48,140	$ 29,471	$ (672,132)	$ 108,923	$ (175,750)
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income (loss) from continuing operations attributable to Acadia Healthcare Company, Inc.	$ 0.51	$ 0.51	$ 0.34	$ 0.24	$ (0.15)	$ 0.28	$ 0.31	$ 0.16	$ 1.60	$ 0.59	$ 0.66
Income (loss) from discontinued operations	(9.42)	(0.09)	0.13	0.14	0.02	0.21	0.24	0.18	(9.25)	0.65	(2.67)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	(8.91)	0.42	0.47	0.38	(0.13)	0.49	0.55	0.34	(7.65)	1.24	(2.01)
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income (loss) from continuing operations attributable to Acadia Healthcare Company, Inc.	0.50	0.50	0.34	0.23	(0.15)	0.28	0.31	0.15	1.58	0.59	0.65
Income (loss) from discontinued operations	(9.28)	(0.08)	0.12	0.15	0.02	0.20	0.24	0.19	(9.17)	0.65	(2.66)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$ (8.78)	$ 0.42	$ 0.46	$ 0.38	$ (0.13)	$ 0.48	$ 0.55	$ 0.34	$ (7.59)	$ 1.24	$ (2.01)

Quarterly Information (Unaudited) - Schedule of Quarterly Financial Information (Parenthetical) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Quarterly Financial Information [Line Items]
Loss on impairment	$ 4,751	$ 27,217
Discontinued Operations [Member] \| U.K. Sales [Member]
Quarterly Financial Information [Line Items]
Loss on sale	(867,300)
Non-cash goodwill impairment	$ 356,200
Loss on impairment		$ 27,200

Financial Information for the Company and Its Subsidiaries - Additional Information (Detail)	Dec. 31, 2020	Oct. 14, 2020	Jun. 24, 2020	Dec. 31, 2019	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.125%			6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.125%			5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%			5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.50%			6.50%	6.50%
5.500% Senior Notes due 2028 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.50%		5.50%	5.50%
5.000% Senior Notes due 2029 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.00%	5.00%		5.00%

Financial Information for the Company and Its Subsidiaries - Summarized Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Financial Statements, Captions [Line Items]
Current assets	$ 2,523,395	$ 542,211
Property and equipment, net	1,622,896	1,499,587
Goodwill	2,105,264	2,085,104	$ 2,044,837
Current liabilities	1,308,185	463,576
Long-term debt	2,968,948	3,105,420
Redeemable noncontrolling interests	55,315	33,151	28,806
Total equity	1,899,456	2,505,381	$ 2,333,307	$ 2,572,871
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Current assets	654,735	421,653
Property and equipment, net	1,421,875	1,313,830
Goodwill	1,992,305	1,992,344
Total noncurrent assets	3,640,809	3,516,967
Current liabilities	626,419	305,131
Long-term debt	2,786,125	2,877,602
Total noncurrent liabilities	3,045,981	3,159,489
Total equity	$ 623,144	$ 474,000

Financial Information for the Company and Its Subsidiaries - Summarized Statements of Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Condensed Financial Statements, Captions [Line Items]
Revenue	$ 541,276	$ 547,961	$ 491,475	$ 509,217	$ 501,225	$ 509,383	$ 509,813	$ 487,960	$ 2,089,929	$ 2,008,381	$ 1,904,695
Income from continuing operations before income taxes									183,797	78,395	67,395
Net loss									(669,199)	110,122	(175,486)
Net loss attributable to Acadia Healthcare Company, Inc.	$ (783,672)	$ 36,998	$ 41,079	$ 33,463	$ (11,254)	$ 42,566	$ 48,140	$ 29,471	(672,132)	$ 108,923	$ (175,750)
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue									1,943,734
Income from continuing operations before income taxes									161,293
Net loss									(269,231)
Net loss attributable to Acadia Healthcare Company, Inc.									$ (269,231)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

Subsequent Events - Additional Information (Detail) - USD ($)	Jan. 29, 2021	Jan. 19, 2021	Jan. 05, 2021
Tranche B-4 Facilities [Member]
Subsequent Event [Line Items]
Repayments of debt		$ 767,900,000	$ 105,000,000.0
Term Loan A- Facility [Member]
Subsequent Event [Line Items]
Repayments of debt		311,700,000
Subsequent Event [Member] \| Redemption of 5.265% Senior Notes [Member]
Subsequent Event [Line Items]
Senior Notes	$ 650,000,000
Debt instrument interest rate	5.265%
Subsequent Event [Member] \| Redemption of 6.500% Senior Notes [Member]
Subsequent Event [Line Items]
Senior Notes	$ 390,000,000
Debt instrument interest rate	6.50%
Subsequent Event [Member] \| Redemption of 5.265% Senior Notes and 6.500% Senior Notes [Member]
Subsequent Event [Line Items]
Debt instrument, redemption date	Jan. 29, 2021
Senior Notes	$ 1,040,000,000
Payment of breakage costs	6,000,000
Estimated transaction costs	9,000,000
Debt instrument funded from cash	430,000,000
Proceeds from new senior secured credit facility	$ 625,000,000
Debt instrument term	5 years
Discontinued Operations [Member] \| U.K. Sales [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Gross proceeds from sale of business		1,525,000,000
Cash retained by buyer		75,000,000
Transaction costs		16,000,000
Settlement of existing foreign currency hedging liabilities		85,000,000
Net proceeds from sale of business		1,425,000,000
Net proceeds from sale of business, after deducting cash retained by buyer		1,350,000,000
Cash		345,000,000
Discontinued Operations [Member] \| U.K. Sales [Member] \| Subsequent Event [Member] \| Tranche B-4 Facilities [Member]
Subsequent Event [Line Items]
Repayments of debt		768,000,000
Discontinued Operations [Member] \| U.K. Sales [Member] \| Subsequent Event [Member] \| Term Loan A- Facility [Member]
Subsequent Event [Line Items]
Repayments of debt		$ 312,000,000